Cocrystals of nutraceuticals: Protocatechuic acid and quercetin by Pujari, Twarita Anil
University of South Florida
Scholar Commons
Graduate Theses and Dissertations Graduate School
2009
Cocrystals of nutraceuticals: Protocatechuic acid
and quercetin
Twarita Anil Pujari
University of South Florida
Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the American Studies Commons
This Thesis is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate
Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact scholarcommons@usf.edu.
Scholar Commons Citation
Pujari, Twarita Anil, "Cocrystals of nutraceuticals: Protocatechuic acid and quercetin" (2009). Graduate Theses and Dissertations.
http://scholarcommons.usf.edu/etd/2156
 Cocrystals of Nutraceuticals: Protocatechuic Acid and Quercetin 
 
 
by 
 
 
 
Twarita Anil Pujari 
 
 
 
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of 
Master of Science 
Department of Chemistry 
College of Arts and Sciences 
University of South Florida 
 
 
 
 
Major Professor: Michael J. Zaworotko, Ph.D. 
Mohamed Eddaoudi, Phd. 
Abdul Malik, Ph.D 
 
 
 
Date of Approval: 
July 17, 2009 
 
 
 
Keywords: supramolecular chemistry, bioavailability, hydrogen bond, bcs classification, 
solubility 
 
© Copyright 2009 , Twarita Anil Pujari
 || KRISHANARPANMASTU || 
|| AVADHUT CHINTAN SHREE GURUDEV DATTA ||  
 
 ACKNOWLEDGEMENTS 
I would like to express my sincere thanks to my professor Dr. Michael J. 
Zaworotko for giving me an opportunity to conduct research under his expert 
supervision. His valuable guidance will go a long way towards my passion in 
chemistry.  
I am also thankful to Dr. Wayne C. Guida and Dr. Abdul Malik for being my 
committee members and giving me useful suggestions and encouragement.   
Big thanks to all my colleagues for their support. I will cherish all brainstorming 
sessions blended with fun times. I also thank Faculty and Staff of the Department of 
Chemistry, University of South Florida, for their friendly accommodation. 
A special thanks to Dr. B.G. Ugarkar, Dr. R.C. Chikate, Dr. A.D. Natu, Dr. M.J. 
Pujari, late Dr. S.Y.Gadre and all other professors for building my chemistry 
foundation.  
I can‟t be grateful enough to my parents, in laws, and all near and dear ones for 
their constant encouragement. My heartfelt thanks to our pillar of support, my 
grandfather, whose principles I idealize. Aba, you are always with us! 
I don‟t have enough words to express my deep thanks to Parag, my husband. 
Without his love and constant support it would have not been achievable. 
i 
 
TABLE OF CONTENTS 
LIST OF TABLES iv 
LIST OF FIGURES v 
ABSTRACT ix 
1. INTRODUCTION 1 
     1.1 Nutraceuticals 1 
     1.2 Crystal Engineering 2 
            1.2.1 Supramolecular Chemistry 3 
            1.2.2 Supramolecular Synthons 3 
            1.2.3 Cocrystals 4 
  1.2.4 Pharmaceutical Cocrystals 6 
  1.2.5 Nutraceutical Cocrystals 11 
  1.2.6 Synthesis of Cocrystals 11 
 1.3 Solubility and Bioavailability  11 
  1.3.1 Noyes-Whitney Equation 12 
  1.3.2 BCS Classification 12 
 1.4 Cocrystal Design 13 
  1.4.1 Cambridge Structural Database (CSD) 13 
  1.4.2 CSD Statistics for Acids and Phenols 14 
  1.4.3 Cocrystal Formers  22 
ii 
 
 1.5 References 26 
2. PROTOCATECHUIC ACID  30 
 2.1 Introduction 30 
  2.1.1 Protocatechuic acid in CSD 31 
 2.2 Cocrystals of Protocatechuic acid 32 
  2.2.1 Experimental Section  33 
  2.2.2 Cocrystallization via Solution Crystallization 33 
  2.2.3 Cocrystallization via Grinding and Slurry conversion 36 
  2.2.4 FTIR, PXRD, Differential Scanning Calorimetry and Thermo 
           Gravimetric Analysis 37 
  2.2.5 Determination of Crystal Structure 45 
  2.2.6 Results and Discussion 51 
 2.3 Dissolution studies 65 
 2.4 References 66 
3. QUERCETIN 69 
 3.1 Introduction 69 
  3.1.1 Quercetin in CSD 69 
 3.2 Cocrystals of Quercetin 71 
  3.2.1 Experimental Section 71 
  3.2.2 Cocrystallization via Solution Crystallization 72 
  3.2.3 Cocrystallization via Grinding and Slurry conversion 73 
  3.2.4 FTIR, PXRD, Differential Scanning Calorimetry and Thermo  
           Gravimertic Analysis 74 
  3.2.5 Determination of Crystal Structure 78 
iii 
 
  3.2.6 Results and Discussion 79 
 3.3 Dissolution Studies 84 
 3.4 References  87 
4. CONCLUSION AND FUTURE DIRECTION 88  
iv 
 
LIST OF TABLES 
Table 1.1: Summary of the CSD statistics for phenols with other functionalities 18       
Table 1.2: Summary of the CSD statistics for acids with other functionalities 22      
Table 1.3: Cocrystal formers containing amide functionality 23           
Table 1.4: Cocrystal formers containing purines 24 
Table 1.5: Cocrystal formers containing aromatic nitrogen base 25 
Table 2.1: Summary of the cocrystals of PA synthesized    33 
Table 2.2: Comparison of solvent evaporation, grinding and slurry techniques 37   
Table 2.3: Crystallographic data of cocrystals of PA 50      
Table 2.4: C-N-C angles in neutral isonicotinamide cocrystals from CSD 55 
Table 2.5: C-N-C angles in neutral nicotinamide cocrystals from CSD 61 
Table 3.1: Summary of cocrystals of quercetin obtained    72 
Table 3.2: Comparison of solvent evaporation, grinding and slurry techniques 73   
Table 3.3: Crystallographic data for cocrystals of quercetin    78 
v 
 
LIST OF FIGURES 
Figure 1.1: Relationship between nutraceuticals and other health products 1       
Figure 1.2: Examples of supramolecular (a) carboxylic acid homosynthon 
                  (b) carboxylic acid
…
pyridine heterosynthon 4  
Figure 1.3: Crystal structure of the triclinic form of quinhydrone 4             
Figure 1.4: The Hoogsteen base-pair  5 
Figure 1.5: Representation of pharmaceutical cocrsytal 6 
Figure 1.6: 1:1 cocrystal of carbamazepine-saccarine 7  
Figure 1.7: Dissolution profiles of Intraconazole and its cocrystals 8 
Figure 1.8: Dissolution profile of fluoxetine HCl and its cocrystals 8 
Figure 1.9: Hydrogen bonding interactions between the carboxylic acid of the   
                   glutaric acid molecule with amide and pyridine groups of the drug 
                   molecule  9  
Figure 1.10: Dog plasma concentration with time for (a) 5 mg/kg dosing and (b)   
                     50 mg/kg dosing of a drug (dark circles) and cocrystal (open circles)   9 
Figure 1.11: 1:1 cocrystal of melamine and cyanuric acid 10 
Figure 1.12: The Biopharmaceutics Classification System (BCS) as defined by   
                     the FDA 13  
 
Figure 1.13: Identification of supramolecular synthons using CSD 14 
Figure 1.14: (a) Supramolecular OH
…
OH homosynthon (b) Histogram of   
                    OH
…
O hydrogen bond lengths in phenols 15  
Figure 1.15: (a) Supramolecular heterosynthon of  phenolic OH
…
Narom (b)   
                    Histogram of OH
…
Narom hydrogen bond lengths in phenols 16 
Figure 1.16: Supramolecular heterosynthons in phenol and primary amide 16 
vi 
 
Figure 1.17: (a) Supramolecular heterosynthon in phenol and carbonyl moiety  
                     (aldehyde/ketone) (b) Histogram of OH
…
O=C hydrogen bond lengths  17   
Figure 1.18: Histogram of OH
...
CO   17 
                      
Figure 1.19: Carboxylic acid dimers and catemers 19 
Figure 1.20: Histogram of OH
…
O hydrogen bond lengths in carboxylic    
                     acid dimers retrieved from CSD  19 
Figure 1.21: (a) COOH
…
Narom supramolecular heterosynthon (b) Histograms    
                     of OH
…
Narom hydrogen bond lengths in carboxylic acid
…
aromatic  
                     nitrogen bases retrieved from CSD  20 
Figure 1.22: (a) COOH
…
O=C supramolecular heterosynthon (b) Histograms   
                     of COOH
…
O=C hydrogen bond lengths in carboxylic acid with  
                     carbonyl functionality  20 
Figure 1.23: (a) COOH
…
CONH2 supramolecular heterosynthon (b) Histograms    
                     of NH2
…
O=C hydrogen bond lengths (c) Histograms of OH
…
O=C  
                     hydrogen bond lengths in carboxylic acid with amide functionality  21 
Figure 2.1: Structure of Protocatechuic acid (PA) 30 
Figure 2.2: A popular Roselle variety 31 
Figure 2.3: Hydrogen bonding in Protocatechuic acid monohydrate 31 
Figure 2.4: Hydrogen bonding in Protocatechuic acid acetonitrile solvate 32 
Figure 2.5: Synthesis and single crystal of 1 34 
Figure 2.6: Synthesis and single crystal of 2 34 
Figure 2.7: Synthesis and single crystal of 3 35 
Figure 2.8: Synthesis and single crystal of 5 35 
Figure 2.9: Synthesis of 6  36 
Figure 2.10: Synthesis and single crystal of 7 36   
Figure 2.11: Cocrystal 1: (a) PXRD comparison (b) DSC (C) IR 39  
Figure 2.12: Cocrystal 2: (a) PXRD comparison (b) DSC (C) IR 40 
vii 
 
Figure 2.13: Cocrystal 3: (a) PXRD comparison (b) TGA (C) DSC (d) IR 42 
Figure 2.14: Cocrystal 4: (a) PXRD comparison (b) DSC (C) IR  44 
Figure 2.15: Cocrystal 5: (a) PXRD comparison (b) DSC (C) IR 45 
Figure 2.16: Cocrystal 6: (a) PXRD comparison (b) DSC (c) IR 47 
Figure 2.17: Cocrystal 7: (a) PXRD comparison (b) TGA (c) IR (d) DSC   
                    before heating (e) DSC after heating  49  
Figure 2.18: Each PA molecule is hydrogen bonded to three molecules  
                     of ε-caprolactam through phenol…carbonyl supramolecular  
                     heterosynthon 51  
Figure 2.19: Formation of a tape with alternate PA and isonicotinamide    
                     molecules by acid
…
pyridine supramolecular heterosynthon  52 
Figure 2.20: One molecule of PA is hydrogen bonded to five molecules of   
                     isonicotinamide  53 
Figure 2.21: PA molecules forming acid-acid supramolecular homosynthon and   
                     supramolecular heterosynthons with two water molecules and one 
                     isonicotinic acid molecule.  56 
Figure 2.22: Formation of isonicotinic acid chains in 3 56 
Figure 2.23: Acid dimer of PA molecules forming supramolecular heterosynthon  58 
                     with theophylline dimers 
Figure 2.24: Formation of sheets in 5 59 
Figure 2.25: One molecule of PA is hydrogen bonded to two molecules   
                     of PA through OH
…
OH supramolecular homosynthon, one  
                     molecule of nicotinamide through acid
…
amide supramolecular  
                     heterosynthon and with another nicotinamide molecule  
                     through OH
…
NH2 supramolecular heterosynthon 60 
Figure 2.26: Overall packing of 6 61 
Figure 2.27: Chains of disordered PA and water molecules hydrogen bond with   61   
                     carbamazepine dimers  
Figure 2.28: Comparison of dissolution profiles of PA and its cocrystals 64 
Figure 2.29: Pi stacking in (a) PA nicotinamide (b) PA isonicotinamide cocrystals 65 
viii 
 
Figure 3.1: Structure of quercetin 68 
Figure 3.2: OH
…
carbonyl supramolecular heterosynthon in quercetin dihydrate 70 
Figure 3.3: Intermolecular interactions in the 1:1:1 cocrystal solvate of quercetin,  70 
                   caffeine and methanol  
Figure 3.4: Intermolecular interactions in the 1:1 Quercetin-Isonicotinamide   
                  cocrystal 71   
Figure 3.5: Synthesis and single crystal of 1  72 
Figure 3.6: Synthesis and single crystal of 2 73 
Figure 3.7: Cocrystal 1: (a) PXRD comparison (b) TGA (c) DSC (d) IR 75 
Figure 3.8: Cocrystal 2: (a) PXRD comparison (b) TGA (c) DSC (d) IR 77 
Figure 3.9: Quercetin dimers hydrogen bonding with isonicotinic acid molecules  
                   through phenol…carboxylate supramolcular heterosynthon 79 
Figure 3.10: Formation of a chain of isonicotinic acid molecules with acid-pyridin 
                     supramolecular heterosynthon 80 
Figure 3.11: DSC after heating cocrystal 1 81 
Figure 3.12: Quercetin dimer hydrogen bonding with one theobromine molecule  
                     through carbonyl-phenol supramolecular heterosynthon 81 
Figure 3.13: Formation of sheet structure in 2 82 
Figure 3.14: (a) PXRD pattern (b) DSC (C) TGA of attempts of synthesizing  
                     anhydrous cocrystal of 2 84 
Figure 3.15: Dissolution profiles of dihydrate of 1:1 cocrystal of quercetin and   
                     theobromine, in 1:1 EtOH/Water (V/V%) system at 360 nm 85 
  
ix 
 
COCRYSTALS OF NURACEUTICALS: PROTOCATECHUIC ACID AND 
QUERCETIN 
Twarita Anil Pujari 
ABSTRACT 
The cocrystallization of two or more pure compounds by crystal engineering to 
create a new functional material is of a great academic and industrial interest. 
Pharmaceutical cocrystallization has allured a lot of attention by means of altering the 
physicochemical properties of Active Pharmaceutical Ingredient (API) such as solubility, 
stability and bioavailability. Crystal engineering of nutraceuticals can produce novel 
compounds such as pharmaceutical cocrystals. To establish the importance of 
nutraceutical cocrystallization and its use; polyphenols, a major class of nutraceuticals 
and potential disease preventing agents, are the appropriate targets.  
The work herein focuses on two polyphenols, protocatechuic acid and quercetin, 
which are strong antioxidants. The cocrystals of quercetin have been synthesized, aiming 
to modify its poor water solubility and bioavailability which limits its usage. On the other 
hand, cocrystals of water soluble protocatechuic acid are also prepared to establish its use 
as a cocrystal former. Seven novel cocrystals of protocatechuic acid and two novel 
cocrystals of quercetin are obtained and are characterized by FTIR, DSC (Differential 
Scanning Calorimetry), PXRD (Powder X-Ray Diffraction), single crystal x-ray 
diffraction and TGA (Thermo Gravimetric Analysis). The new crystal forms have also 
been studied via dissolution. Dissolution studies show alteration in solubility of a target 
molecule by its cocrystal irrespective of solubility of the cocrystal former. Overall, the 
study helps in understanding the role of crystal engineering and its utility.
1 
 
1. INTRODUCTION 
1.1 Nutraceutical 
Nutraceutical is the term used to describe a medicinal or nutritional component 
which is present in food, plant or any naturally occurring material and which is used for 
improvement of health by preventing or treating a disease.
1
 Nutraceuticals overlap with 
the other health products such as pharmaceuticals and herbals.
1 
The complex relationship 
is shown in Figure 1.1. 
 
 
Figure 1.1 Relationship between nutraceuticals and other health products 
Pharmaceuticals are usually classed as medicines by law however nutraceuticals 
are available over the counter.
2
 Dr. Stephen De Felice, founder and chairman of the 
Foundation for Innovation in Medicine (FIM, USA), first coined the term Nutraceuticals 
in 1976.
3
 He defined it  as a food, or parts of food, that provide medical or health 
benefits, including the prevention and treatment of disease.
1 
The broad usage includes 
supplementation for poor diet, to improve overall health, to delay the onset of age-related 
diseases, for stress, after illness etc.
1
 However dietary supplements in the US can be 
2 
 
marketed without FDA approval. Thus Foundation for the Innovation in Medicine (FIM) 
introduced the Nutraceutical Research and Education Act in Congress in October 1999.
 1 
It helped nutraceuticals to establish a new legal classification.
4 
Nutraceuticals are 
popularly available in forms of tablets, capsules, softgels, soft chews etc.
1
 
An American survey of consumer preferences for different formulations, carried 
out in 2004 reveals that new drug delivery systems such as chewing gums and patches are 
overcoming the traditional forms such as capsules.
5 
Nutraceuticals includes wide range of 
products such as polyphenols (Epigallocatechin gallate (EGCG) from tea or resveratrol 
from red grapes), vitamins, oils from fish and flax, calcium fortified juices, theobromine 
from cacao tree, caffeine from coffee leaves etc.
1
 
 
 1.2 Crystal Engineering 
 A crystal, solid material, in which molecules are arranged in an orderly repeating 
pattern extending in all three spatial dimensions, is an ultimate case of molecular 
recognition. A series of complex molecular recognition with high level of precision 
describes crystal as “supermolecules par excellence”.6 The rational design of new 
crystalline materials led to the development of new field of crystal engineering.
7
 In 1955, 
R. Pepinsky first coined the term crystal engineering who crystallized organic ions with 
metal containing complexes.
8
 Subsequently in 1971, G.M.J. Schmidt implemented it in 
the photodimerization of cinnamic acid.
9
 A working definition of crystal engineering was 
given by Dr. Desiraju in 1989 , “crystal engineering is the understanding of 
intermolecular interactions in the context of crystal packing and in the utilization of such 
understanding in the design of new solids with desired physical and chemical 
properties.”10 Crystal engineering has been explored vastly in different applications such 
as non-linear optics (NLO)
 11
, porous materials,
12
 photographic materials
13
 and 
coordination polymers.
14
 Pharmaceutical, one of the most significant sector, has started 
utilizing the concept of crystal engineering very recently and it has been noted that crystal 
engineering has a great impact on Active Pharmaceutical Ingredients (APIs). APIs are 
among the most valuable crystalline substances and crystal engineering has been 
successfully applied in the generation of cocrystals of APIs with improved  
3 
 
physicochemical properties.
15,31 
 
1.2.1 Supramolecular Chemistry 
 Supramolecular chemistry is referred as chemistry beyond the molecules. 
Traditional chemistry focuses on covalent bond while supramolecular chemistry deals 
with noncovalent interactions. In 1890 Nobel laureate Hermann Emil Fischer suggested 
that enzyme-substrate interactions take the form of a "lock and key", pre-empting the 
concepts of molecular recognition and host-guest chemistry. Gradually noncovalent 
bonds were understood in more detail and the importance of supramolecular chemistry 
was well established by 1987. Nobel Prize for chemistry was awarded to Donald J. Cram, 
Jean-Marie Lehn and Charles J. Pedersen in recognition of their work in this area.
17
  
Supramolecular chemistry has wide range of applications in different fields such as 
material technology, catalysis, data storage and processing and green chemistry. Apart 
from these; supramolecular chemistry has been used in the development of new 
pharmaceutical therapies by understanding the interactions at a drug binding site.  
Moreover it has a great impact on the studies of drug delivery and protein-protein 
interactions.  
 
1.2.2 Supramolecular Synthons  
In 1967 E.J. Corey introduced a concept of a synthon
18 
as structural units within 
molecules which can be formed and/or assembled by known or conceivable synthetic 
operations. On the similar lines recognizing that crystal engineering is the solid-state 
supramolecular equivalent of organic synthesis a term supramolecular synthon was 
introduced by Dr. Desiraju in 1995.
19
 Supramolecular synthons are „structural units 
within supermolecules which can be formed and/or assembled by known or conceivable 
intermolecular interactions‟. Supramolecular synthons are spatial arrangements of 
intermolecular interactions between complementary functional groups and simplifies 
understanding of a crystal structure. Supramolecular synthons can be separated in two 
distinct categories, Supramolecular homosynthons and supramolecular heterosynthons. 
Supramolecular homosynthons are composed of identical self-complementary 
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functionalities
20
 such as carboxylic acid dimers
21
 (Figure 1.2 a) and amide dimers
22
. 
Supramolecular heterosynthons are composed of different but complementary 
functionalities such as carboxylic acid
…
amide
23
 and carboxylic acid
…
pyridine
24
 (Figure 
1.2 b). 
 
                (a)                                           (b) 
Figure 1.2: Examples of supramolecular (a) carboxylic acid homosynthon (b) 
carboxylic acid···pyridine heterosynthon 
 
1.2.3 Cocrystals 
 Cocrystals are a long known little studied class of compounds. The first entry of a 
cocrystal was reported in 1844 by Wöhler; the cocrystal of benzoquinone and 
hydroquinone (Refcode: QUIDON, Figure 1.3).
25
 Subsequently they were studied as 
organic molecular compounds.
26
 However until 1960 the structural information on 
cocrystals was absent and term complexes came in to the picture.  
 
Figure 1.3: Crystal structure of the triclinic form of quinhydrone 
 In 1960‟s many people came up with different nucleic base complexes27 and the 
term cocrystal was first used in this context.
28
 In 1963, K.Hoogsteen came up with the 
new base pair known as “Hoogsteen base pair” which can be considered as the first 
prototypal cocrystal. He studied the formation and properties of free radicals in a 
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cocrystal between 1-methylthyamine and 9-methyladenine (Refcode: MTHMAD Figure 
1.4). Later the term cocrystal was subsequently popularized by Margaret Etter.29  
 
Figure 1.4: The Hoogsteen base-pair  
 The definition of a cocrystal is still a topic of debate today.
30 
A broad definition of 
a cocrystal was given by Dunitz; “a crystal containing two or more components 
together.”31 In this view hydrates, solvates, inclusion compounds, clathrates can be 
recognized as cocrystals. In Zaworotko research group and others, we have been using a 
definition; “a cocrystal is a stoichiometric multiple component crystal in which all 
components are solid under ambient conditions when in their pure form. These 
components consist of a target molecule or ion and a molecular cocrystal former(s) and 
when in a cocrystal they coexist at the molecular level within a single crystal.”32,33 This 
definition distinguishes cocrystals from the other broad group of multiple component 
compounds.  
 This emerging field of cocrystal allows modifying the composition of matter and 
physicochemical properties of a molecule without breaking or forming a covalent bond. 
Thus there are different applications for cocrystals. The most important field of 
pharmaceutics is discussed in detail in section 1.4. Other relevant fields include solid 
state synthesis and chiral resolution. In 1982 Etter et. al. reported a nucleophilic 
substitution reaction, the first reaction in the context of  solid state synthesis.
34
 Recently 
Cheney et. al. have reported the condensation of amines and acid anhydrides synthesizing 
imides.
35
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 In 1848 Louis Pasteur reported spontaneous resolution of sodium ammonium  
Tartrate.
36
 Generally racemates are known to be the result of 90% racemic mixtures.
37
 
Chiral separation being a tedious process, the chiral cocrystal formers can offer an 
enhanced possibility of separating enantiomers by fractional crystallization since the 
resulting cocrystals are diastereomeric in nature. The well known example of chiral 
separation is a spontaneous resolution of racemic mandelic acid by (s)-alanine and (R)-
cystine.
38
 
 
1.2.4 Pharmaceutical Cocrystals 
 An attractive subset of cocrystals is pharmaceutical cocrystals. Pharmaceutical 
cocrystals are defined as “cocrystals in which the target molecule or ion is an active 
pharmaceutical ingredient, API, and it bonds to the cocrystal former(s) through 
hydrogen bonds.”39  
 
Figure 1.5: Representation of pharmaceutical cocrystal 
 Delivery of an API is generally preferred in a solid dosage form.  API‟s are 
developed in variety of solid forms and administered in different ways such as 
amorphous, salt, polymorphs, solvates.
40
 The properties such as stability, solubility and 
bioavailability of a drug are directed by its solid form. Thus it gives an opportunity to a 
researcher to develop the best suitable form of a drug with improved physicochemical 
properties.  
 First pharmaceutical cocrystal was reported in 1934 by Heyden et al.
 41
 He 
patented cocrystals of Barbiturates with 4-oxy-5-nitropyridine, 2-ethoxy-5-
acetaminopyridine, N-methyl-alpha-pyridone and -aminopyridine. Complexes of a class 
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of -lactam antibiotics with parabens and related compounds were patented by Eli-Lilly 
in 1995.
42
 Scientific literature database is getting enriched with number of  
pharmaceutical cocrystals with improved physicochemical properties. 
Carbamazepine: Saccharin 1:1 cocrystal (UNEZAO01) (Figure 1.6), developed 
in 2003 by Almarsson and coworkers, was studied in vivo in dogs for their oral 
pharmacokinetics. It showed the improved bioavailability than the marketed 
carbamazepine drug, Tegretol®.
43
  
 
Figure 1.6: 1:1 cocrystal of carbamazepine-saccarine  
 Sporanox® capsules containing itraconazole as an active ingredient used as an 
antifungal agent and is extremely water insoluble. The aqueous dissolution of 2:1 
cocrystal of itraconazole and succinic acid and other two cocrystals were studied in 0.1 N 
HCl at 25°C which showed the improved dissolution profile (Figure 1.7). 
Pharmacokinetic study of itraconazole cocrystals also revealed that cocrystal formulation 
of the API gives similar oral bioavailability to the Sporanox® form in the animal trial 
using a dog model.
44
  
8 
 
 
Figure 1.7: Dissolution profiles of Intraconazole and its cocrystals 
Prozac®, an antidepressant drug, contains Fluoxetine hydrochloride as an API. In 
2004, Childs et.al studied dissolution profile of the three cocrystals of fluoxine HCl in 
water (Figure 1.8).
45
 Fluoxetine HCl: Succinic acid cocrystal showed two fold increase in 
solubility as compared to fluoxetine HCl itself. It has also been observed that cocrystal 
may decrease the solubility as in the case of fluoxetine HCl: benzoic acid. 
 
Figure 1.8: Dissolution profile of fluoxetine HCl and its cocrystals 
9 
 
 2-[4-(4-chloro-2-fluorophenoxy) phenyl] pyrimidine-4-carboxamide, a sodium 
channel blocker (SCB), was developed for the treatment and prevention of surgical, 
chronic and neuropathic pain. Many formulation trials failed to improve the 
bioavailability of a drug. 1:1 cocrystal of a drug (SCB) with glutaric acid (Figure 1.9) 
which was one of the hit from cocrystal screening showed physical and chemical stability 
of a drug. Cocrystal increases in vitro rate of dissolution by 18 times when compared to 
the pure API (Figure 1.10). Bioavailability studies on dogs confirmed that the cocrystal 
improved the plasma AUC values by three times at both low (5 mg/kg) and high dose (50 
mg/kg).
46
 
  
Figure 1.9: Hydrogen bonding interactions between the carboxylic acid of the 
glutaric acid molecule with the amide and pyridine groups of the drug molecule 
 
Figure 1.10: Dog plasma concentration with time for (a) 5 mg/kg dosing and (b) 50 
mg/kg dosing of a drug (dark circles) and cocrystal (open circles) 
10 
 
 The cocrystal of Sildenafil citrate (active pharmaceutical ingredient in Viagra ®) 
with aspirin was patented in 2007 which showed the improved solubility properties in 
acidic conditions. Also it has shown the thermodynamic stability up to 165
0
C.
47 
 
Amgen developed a transient receptor potential vanilloid 1 antagonist, AMG 517, 
for treatment of acute and chronic pain. The free base of AMG 517 is associated with 
problems such as insolubility in water and buffers at physiological pH. Bak and 
coworkers
48
 synthesized 10 cocrystals of AMG 517 and the physicochemical properties 
such as particle size, solubility, stability, hygroscopicity, thermal behavior and structural 
characteristics of these cocrystals were studied in detail. Further the solubility studies of 
these cocrystals showed the increase in solubility and their conversion to AMG 517 
hydrate. 
 In early 2007, pet food crisis, was observed in China. More than 24,000 clinical 
assessments were found with acute renal failure within 3 months in Hong Kong. It was 
observed that melamine, protein content in the pet food, forms a cocrystal with cyanuric 
acid (QACSUI), another content of pet food. Even though melamine and cyanuric acid 
are nontoxic individually the resulting 1:1 cocrystal (Figure 1.11) is highly insoluble in 
water resulting in toxic kidney stones. It is a first example of cocrystals altering clinically 
relevant physical properties in a negative manner.
49
 
 
Figure 1.11: 1:1 cocrystal of melamine and cyanuric acid 
 Cocrystals or pharmaceutical cocrystals are novel as they can afford crystal  
form diversity. The utility in terms of improving physicochemical properties of a drug 
represents an opportunity to patent and market, clinically improved crystal forms of 
available drugs in form of new drugs. In conclusion cocrystals and pharmaceutical 
cocrystals are offering new avenues to the pharmaceutical industry.  
11 
 
1.2.5 Nutraceutical Cocrystals 
 As explained in 1.1 nutraceuticals are the naturally occuring nutritional products 
that have health-related benefits and thus have an added advantage over pharmaceuticals. 
Many nutraceuticals have a proven record in drug discovery such as aspirin and 
penicillin. Nutraceuticals have established safety record and are readily available under 
Good Manufacturing Practices (GMP). This will speed up the drug to clinic by lowering 
the preclinical burden and toxicity risk. Even though nutraceuticals are the potential drug 
candidates, many of them possess low water solubility and hence bioavailability. 
Improving bioavailability by synthesizing a nutraceutical cocrystal has a large intellectual 
property potential. On the other hand, highly water soluble, being safe, can serve as a 
cocrystal former for a less soluble API to improve its solubility. 
 
1.2.6 Synthesis of Cocrystals 
 A range of methodologies for the synthesis of cocrystals has been reported in the 
literature. Single crystals are commonly developed via slow evaporation of a solution 
containing stoichiometric amounts of target molecule and cocrystal former. The choice of 
the solvent is crucial in obtaining a cocrystal since role of a solvent in nucleation of 
crystals is poorly understood. Solid state grinding has been established from 19
th
 century.  
The very first cocrystal of quinone and hydroquinone was synthesized via grinding.
25
 The 
technique of adding small amount of solvent i.e. solvent drop grinding or liquid assisted 
grinding was shown to promote cocrystal formation.
50
 Automated grinding ballmills are 
also developed for efficient synthesis. Another technique is the growth from melt in 
which two components are placed together and melt is formed.
51
 The resulting solution is 
seeded by remaining solid material and a cocrystal is formed. Slurry preparation,
52
 
sublimation are the other suitable methodologies.   
 
1.3 Solubility and Bioavailability 
 Solubility and bioavailability of a drug are important parameters in drug 
development process. Intrinsic solubility and dissolution of a drug are prerequisites for 
oral drug delivery. The fundamentals of the dissolution are studied by Noyes-Whitney 
12 
 
equation
53
 and the correlation of it with bioavailability leads to a Biopharmaceutics 
Classification system (BCS).  
 
1.3.1 Noyes-Whitney Equation  
 In 1897 the first dissolution experiment was performed by Noyes and Whitney for  
benzoic acid and lead chloride.
53
The observations of this experiment was formulated in  
terms of law which was expressed as,  the rate at which a solid substance dissolves in its 
own solution is proportional to the difference between the concentration of that solution 
and concentration of the saturated solution. Its mathematical expression is as follows,  
 
Where CS represents the solubility of the substance or the concentration of its saturated 
solution; C the concentration at the expiration of time t and k a constant. Further with the 
series of the experiment in 1900 Erich Brunner and Stanislaus von Tolloczko showed that 
the rate of the dissolution depends on the exposed surface, the rate of the stirring, 
temperature, structure of the surface and the arrangement of the apparatus.
54
 Thus 
modified mathematical expression came out to be, 
 
Where k1 is constant and S is the surface area. It implemented that the rate of dissolution 
of a drug will increase if the bulk solubility will increase.
55
 In the period of 1950-1980 
series of experiments showed that the rate of dissolution affects the bioavailability of 
drug. And it is now well recognized that bioavailability gets influenced critically by 
solubility.  
 
1.3.2 BCS Classification 
While understanding the complexity of the drug absorption process Amidon and 
coworkers developed a simplified macroscopic approach and correlated drug absorption 
and intestinal permeability.
56
 In addition, they developed a model for water insoluble 
drugs. From these models it was well established that drug absorption is controlled by 
13 
 
three factors; absorption number, dissolution number and dose number. All these 
observations lead them to set a standard for drug bioavailability and Biopharmaceutics 
Classification System (BCS) was proposed. According to BCS a substance is classified on 
the basis of its aqueous solubility and intestinal permeability, and four drug classes were 
defined i.e., high solubility/high permeability (Class I), low solubility/high permeability 
(Class II), high solubility/low permeability (Class III), low solubility/low permeability 
(Class IV) (Figure 1.12). 
According to BCS a drug substance is considered highly soluble when the highest 
strength is soluble in 250 ml or less of aqueous media over the pH range of 1.0–7.5; 
otherwise, the drug substance is considered to be poorly soluble.
57
 
BCS class II drugs present a challenge to cocrystallization field where cocrystals 
can make a difference by altering the bulk solubility of a drug and hence altering the rate 
of a dissolution and furthermore the bioavailability of an API. It has already been 
demonstrated with cocrystals of carbamazepine, itraconazole and fluoxetine 
hydrochloride as explained in section 1.2.4. 
 
Figure 1.12: The Biopharmaceutics Classification System as defined by the FDA 
 
1.4 Cocrystal Design 
1.4.1 Cambridge Structural Database (CSD) 
 A prerequisite in cocrystal design is Cambridge Structural Database (CSD). 
CSD is a database that was developed in 1965 at Cambridge University by Olga 
14 
 
Kennard.
58
 CSD is a depository of X-ray and neutron diffraction data of organics, 
organometallics and metal complexes containing up to 500 non-H atoms. The database is 
a collection of bibliographic, information referencing the chemical connectivity in terms 
of two dimensional (2D) structural formula and three dimensional (3D) molecular 
structure and crystallographic data such as unit cell dimensions, space group, atomic 
coordinate data (3D crystal structure). 
CSD comprises of mainly four programs. ConQuest allows searching and 
retrieving the information, Mercury for structure visualization, Vista  gives numerical 
analysis and PreQuest which is used for database creation. CSD database is rapidly 
increasing and August 2008 release contains structural information of 456,628 organic, 
metal-organic and organometallic crystal structures.  
Designing a cocrystal first involves a CSD survey which helps in the 
identification and understanding of supramolecular synthons of functional groups present 
in target molecule. Analysis of intermolecular contacts facilitates the selection of a 
cocrystal former.  
 
Figure 1.13: Identification of supramolecular synthons using CSD 
 
1.4.2 CSD statistics for Acids and Phenols 
 The chosen targeted molecules for the study contain phenol and acid 
functionalities. Thus it is necessary to know about the statistics of existing synthons of 
acid and phenol with other functional groups present in the CSD. All searches were 
carried out by considering following constraints: no ions, only organics, R factor: ≤ 7.5% 
and structures with 3D coordinates. The raw data includes any datasets with competing 
hydrogen bonding functionality and refined data excludes the same. 
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OH OH
 
 
  
Figure 1.14: (a) Supramolecular OH
…
OH homosynthon (b) Histogram of OH
…
O 
hydrogen bond lengths in phenols 
The CSD analysis reveals 7193 entries containing at least one phenolic OH 
moiety.  Phenols can form supramolecular homosynthon (Figure 1.14a). The raw search 
contains 1028 (14.29%) entries that exhibit OH
…
OH supramolecular homosynthon. The 
percentage of supramolecular homosynthon increases to around 59% when competing 
functionalities are absent. Figure 1.14b shows the histogram for OH
…
O hydrogen bond. 
The range of the hydrogen bond is 2.459-3.040 Å with the mean value of 2.809(2) Å. The 
results are summarized in table 1.1. 
There are 690 structures containing both phenolic OH and aromatic nitrogen base, 
out of which 349 (50.58%) entries exhibit OH
…
Narom supramolecular heterosynthon 
(Figure 1.15a) whereas 87 (12.60%) entries contain OH
…
OH supramolecular 
homosynthon. When the competing hydrogen bonding groups are absent, there are 136 
entries containing both phenolic OH and aromatic nitrogen base and out of these 38 
(27.94%) shows OH
…
OH supramolecular homosynthon and 108 (79.41%) contain 
OH
…
Narom supramolecular heterosynthon which explains the reliability of OH
…
Narom 
synthon. The OH···Narom supramolecular heterosynthon occurs within the range 2.515-
3.066 Å (O···N) with an average O···N of 2.746() Å as shown (Figure 1.15b). 
 
(a) (b) 
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Figure 1.15: (a) Supramolecular heterosynthon of  phenolic OH
…
Narom 
(b) Histogram of OH
…
Narom hydrogen bond lengths in phenols 
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Figure 1.16: Supramolecular heterosynthons in phenol and primary amide 
CSD holds 81structures containing both phenol and amide functionalities. Phenols 
can hydrogen bond with amides in two different fashions. Raw data reveals that 
supramolecular homosynthon of amide (30, 37.03%) dominates over the phenol
…
 amide 
supramolecular heterosynthon (Figure 1.16). Statistics obtained from refined data (3) is 
too limited to generalize the hierarchy of these synthons.  
The CSD analysis on phenols and carbonyl moiety was also carried out. It shows 
the presence of 1668 structures. Supramolecular heterosynthon OH
…
O=C (Figure 1.17a) 
is present in 599 (35.91%) entries whereas 212 (12.70%) entries contain the 
supramolecular OH
…
OH homosynthon. The % of supramolecular heterosynthon 
increases to 64% when competing groups are absent. The cut off range for OH
…
O=C is 
2.413-3.038 Å with an average of 2.760(12) Å. 
(a) (b) 
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Figure 1.17: (a) Supramolecular heterosynthon in phenol and carbonyl 
moiety (aldehyde/ketone) (b) Histogram of OH
…
O=C hydrogen bond lengths 
There are 363 entries containing both phenol and acid moieties. 90 (24.79%) of 
them shows phenol-carbonyl OH
…
O=C supramolecular heterosynthon. The cut off range 
for OH
… 
O=C synthons is 2.613-3.039Å with the average value of 2.785(4) Å.  
 
Figure 1.18: Histogram of OH
…
O=C and  
 
 
 
 
 
(a) (b) 
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Table 1.1: Summary of the CSD statistics of phenols with other functionalities 
CSD August 2008 release; Constrains: no ions, only organics, R factor: ≤ 7.5% and 
structures with 3D coordinates 
 
Functional 
group present 
No. of 
structures 
Raw data 
No. of 
structures 
Refined data 
OH (Phenol) 7193 
1028 (14.29%) 
OH
…
OH 
216 
127 (58.79%) 
OH
…
OH 
OH & Narom 690 
87 (12.60%) 
OH
…
OH 
349 (50.58%) 
OH
…
Narom 
136 
38 (27.94%) 
OH
…
OH 
108 (79.41%) 
OH
…
Narom 
OH & 
primary 
amide 
81 
30 (37.03%) 
CONH2
…
CONH2 
15 (18.52%) 
OH
…
O=C(NH2) 
21(25.92%) 
OH
…
NH2 
3 
1 (33.33%) 
CONH2
…
CONH2 
2 (66.67%) 
OH
…
O=C(NH2) 
3 (100%) 
OH
…
NH2 
OH & O=C 1668 
212 (12.70%) 
OH
…
OH 
599 (35.91%) 
OH
…
O=C 
245 
53 (21.63%) 
OH
…
OH 
153 (62.45%) 
OH
…
O=C 
OH & 
carboxylic acid 
363 
70 (19.28%) 
OH
…
OH 
106 (29.20%) 
COOH
…
COOH 
90 (24.79%) 
OH
…
O=C (acid) 
58 
21 (%) 
OH
…
OH 
47 (%) 
COOH
…
COOH 
17 (29.31%) 
OH
…
O=C (acid 
 
Carboxylic acid is one of the important functional group in crystal engineering. 
Carboxylic acid can act as both hydrogen bond donor as well as acceptor thus can form a 
complementary unit with themselves. Two types of association are observed, dimers and 
catemers (Figure 1.19). 
The CSD data reveals 5943 entries which contain at least one carboxylic acid 
functional group. The carboxylic acid dimer was observed in 1871 (31.48%) entries with 
O
…
O range 2.50-3.00 Å with mean value of 2.650 (1) Å and catemers are observed in 
176 (2.96%) entries. Whereas when other functionalities are absent, out of 683 entries 
547 (80%) show acid dimers and 54 (7.9%) show acid catemers. 
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.     Figure 1.19: Carboxylic acid dimers and catemers 
 
 
Figure 1.20: Histogram of OH
…
O hydrogen bond lengths in carboxylic acid dimers 
retrieved from CSD 
20 
 
 
 
 Figure 1.21: (a) COOH
…
Narom supramolecular heterosynthon (b) Histograms of 
OH
…
Narom hydrogen bond lengths in carboxylic acid-aromatic nitrogen bases 
retrieved from CSD 
Further analysis of CSD reveals 645 entries containing both carboxylic acid and 
aromatic nitrogen base. The ability of carboxylic acids and aromatic nitrogen to form 
reliable carboxylic acid-aromatic nitrogen supramolecular heterosynthon has been 
already established.
58 
It shows 94.78% occurrence of COOH-Narom supramolecular 
heterosynthon when other competing groups are not present. The cut off range for the 
synthon is 2.50-3.045 Å with mean value of 2.652 (2) Å.  
 
 
Figure 1.22: (a) COOH
…
O=C supramolecular heterosynthon (b) Histograms 
of COOH
…
O=C hydrogen bond lengths in carboxylic acid with carbonyl 
functionality 
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The analysis of carboxylic acid and carbonyl (aldehydes/ketones) reveals 621 
entries with approximately similar occurrence of supramolecular heterosynthon and 
supramolecular homosynthon. The occurrence of supramolecular heterosynthon increases 
from 26 to 30% in case of refined data but supramolecular homosynthon dominates 
(46.73%). The cut off range for COOH
…
O is 2.451-3.030 Å with mean value of 2.698(6) 
Å. 
The analysis of carboxylic acids and amides reveals that the COOH
…
CONH2 
supramolecular heterosynthon shows 49.44% reliability of occurrence in the presence of 
other competing groups whereas the percentage increases to 64.3% in the absence of 
other hydrogen bonding functionalities. The total number of entries for the refined data is 
limited to 28. The cut off range for NH2
…
O=C is 2.809-3.061 Å with mean value of 
2.940(9) Å and for OH
…
O=C is 2.418-2.713 Å mean 2.564(5) Å. 
 
  
 Figure 1.23: (a) COOH
…
CONH2 supramolecular heterosynthon (b) Histograms of 
NH2
…
O=C hydrogen bond lengths (c) Histograms of OH
…
O=C hydrogen bond 
lengths in carboxylic acid with amide functionality 
All above results for carboxylic acid are summarized in Table 1.2. 
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Table 1.2: Summary of the CSD statistics for acids with other functionalities 
Functional 
group present 
No. of 
structures 
Raw data 
No. of 
structures 
Refined data 
COOH 5943 
1871( 31.48% 
dimers) 
176 (2.96% 
catemer)  
COOH
…
COOH  
683 
547( 80% 
dimers) 
54 (7.9% 
catemer)  
COOH
…
COOH 
COOH & Narom 645 
32 (4.96%) 
COOH
…
COOH 
486 (75.35%) 
COOH
…
Narom 
134 
9 (6.7%) 
COOH
…
COOH 
127 (94.78%) 
COOH
…
Narom 
COOH & 
primary 
amide 
178 
8 (4.49%) 
COOH
…
COOH 
52 (29.21%) 
CONH2
…
CONH2 
88 (49.44%) 
COOH
…
CONH2 
28 
1 
COOH
…
COOH 
3 
CONH2
…
CONH2 
18 (64.3%) 
COOH
…
CONH2 
COOH & O=C 621 
158(25.44%) 
COOH
…
COOH 
164 (26.40%) 
COOH
…
O=C 
199 
93 (46.73%) 
COOH
…
COOH 
78(39.20%) 
COOH
…
O=C 
 
 Upon reviewing the CSD statistics obtained for phenols and acids, aromatic 
nitrogen bases seem to be promising cocrystal formers. Also carbonyls, amides and 
purines would be promising.  
 
1.4.3 Cocrystal formers 
 A cocrystal former hydrogen bonds with the target molecule forming a cocrystal. 
The data obtained from CSD statistics helps us to choose suitable cocrystal formers for a 
target molecule. A cocrystal former must also be pharmaceutically acceptable or even 
approved. Even though the capacity of available cocrystal formers is not fixed they are 
limited to generally regarded as safe (GRAS) or a compound that has already been 
approved by food and drug administration (FDA). Other characteristic features those are 
taken in to an account are solubility, toxicity, pKa and cost. Tables 1.3, 1.4 and 1.5 
summarize the cocrystal formers chosen for targeted molecules. 
 
23 
 
Table 1.3: Cocrystal formers containing amide functionality 
Structure 
Mol. formula, 
Name 
Mol. Wt. 
M.P (
0
C) 
Cost pKa 
LD50 
mg/kg 
Solubility 
mg/ml 
 
C6H11NO 
Caprolactam 
113.16 
68-70 
20.30/500
g 
 
16.61 
Acidic 
-0.14 
basic 
 
1210 
(Rat- 
oral) 
 
4560* 
Soluble 
 
 
 
C6H10N2O2 
Piracetam 
142.16 
153 
47.40/25g 
 
15.67 
Acidic 
-0.62 
basic 
 
12000 
(Mouse-
subcutan
eous) 
 
84  
Soluble 
 
 
C15H12N2O2 
Oxcarbazepine 
252.27 
219-221 
65/10mg 
 
13.73 
basic    
-0.53 
acidic 
 
4470 
(rat, 
oral) 
 
0.35 
Very 
Slightly 
soluble 
 
 
C15H12N2O 
Carbazepine 
236.37 
203-205 
41.70/5g 
 
13.94 ± 
0.20Acid
ic 
 -0.49 ± 
0.20 
basic 
 
4025 
(Rat-
oral) 
 
0.078 
Practically 
Insoluble 
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Table 1.4: Cocrystal formers containing purines 
Structure 
Mol. formula, 
Name 
Mol. Wt. 
M.P (
0
C) 
Cost pKa 
LD50 
mg/kg 
Solubility 
mg/ml 
 
C7H8N4O2  
Theobromine 
180.16 
357-358 
 
 
24.80/25g 
 
9.90 
basic 
0.59acidi
c 
 
300 
(dog) 
 
6.1 
Slightly 
soluble 
 
 
C8H10N4O2 
Caffeine 
194.13 
238 
57.70/250
g 
 
0.73 
basic 
 
355 
(Rat-
oral) 
 
20  
Slightly 
Soluble 
 
 
C5H5N5 
Adenine 
135.13 
361 
63.70/25g 
 
10.43 
basic 
 
745 
(Rat-
oral) 
 
0.976 
Very 
Slightly 
soluble 
 
 
C7H8N4O2  
Theophylline 
180.16 
271 
25.90/100
g 
 
8.60±0.5
0  
Acidic 
1.45±0.7
0  
basic 
 
225 
(Rat- 
oral) 
 
4.1  
Slightly 
soluble 
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Table 1.5: Cocrystal formers containing aromatic nitrogen base 
Structure 
Mol. formula, 
Name 
Mol. Wt. 
M.P (
0
C) 
Cost pKa 
LD50 
mg/kg 
Solubility 
mg/ml 
 C5H8N2 
3,5-dimethyl 
pyrazole 
96.13 
105-108 
49.20/100
g 
 
15.2 
basic 
3.91acidi
c 
 
1060 
(mouse, 
oral) 
 
9  
Slightly 
soluble 
 
 
C8H14N2O2 
Isonicotinamid
e 
122.12 
155-157 
39.40/100
g 
 
14.96 
acidic 
3.39 
basic 
 
- 
106*  
Soluble 
 
 C8H10N4O2 
Nicotinamide 
122.12 
128-130 
18.20/100
g 
 
 
14.83 
acidic 
3.54 
basic 
 
1680 
(Rat-
subcutan
eous) 
 
600*  
Slightly 
soluble 
 
 
C6H4NO2 
Isonicotinic 
acid 
123.11 
>300 
(decomposes)  
 
13.30/50g 
 
1.94 
acidic 
4.88 
basic 
 
3123 
(mouse, 
oral) 
 
16 
Sparingly 
soluble 
 
 
C6H4NO2 
Nicotinic acid 
123.11 
236-239 
 
14.50/100
g 
 
2.17 
basic 
4.82 
acidic 
 
5000 
(rat, 
subcutan
eous) 
 
32 
Sparingly 
soluble 
 
 * Practically determined values 
 
  
N
N
CH3
H3C
H
N
NH2
O
N
NH2
O
N
OH
O
N
OH
O
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2. PROTOCATECHUIC ACID 
2.1 Introduction 
Protocatechuic acid (PA, Figure 2.1), (3,4- dihydroxybenzoic acid, C7H6O4, Mol. 
Wt. 154.12, M.P. 205
0
C) is a phenolic acid
1
 in the broad class of polyphenols of the 
nutraceuticals. It is widely available in oil, vegetables, fruits and tea. It is mainly found in 
Roselle (Hibiscus sabdariffa) (Figure 2.2) which is a species of hibiscus found in old 
world tropics. 
 
Figure 2.1: Structure of Protocatechuic acid (PA) 
PA is a strong antioxidant and in pharmaceutics it has been used as an 
anticarcinogenic agent.
2,3,4
 PA is known for chemoprevention as well as tumor 
progression. It induces apoptosis of human leukemia cells while on the other hand it 
enhances tumor promotion in mouse skin cells.
5
 It has been predicted that higher dosage 
of PA enhances tumor.
6
 The solubility of PA in water is 10mg/ml and LD50 is 800mg/kg 
which makes PA a potential cocrystal former. PA (Figure 2.1) contains two phenolic 
groups and a carboxylic acid group. Both can serve as hydrogen bond donor/acceptor. 
Based on the CSD search, occurrence of supramolecular heterosynthons between 
polyphenols with amides, basic nitrogen and purines would be promising in the context 
of cocrystals. Thus different cocrystal formers containing such functionality were 
selected on the basis of their solubility, toxicity, pKa and cost as summarized in tables 
1.3, 1.4 and 1.5. The study herein focuses to establish the use of PA as a cocrystal former 
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to improve the physicochemical properties of the target molecules. 
  
Figure 2.2: A popular Roselle variety 
 
2.1.1 Protocatechuic acid in CSD 
The CSD analysis on PA revealed that the crystal structure of pure PA is not 
known however there are three polymorphs (four entries) of PA monohydrate (Refcodes: 
BIJDON, BIJDON1, BIJDON2 and BIJDON3) and an entry of PA acetonitrile solvate 
(EDUWUW). Figure 2.3 represents the crystal packing of monohydrate of PA for ref 
code BIJDON3. The coordinates for BIJDON, BIJDON1 and BIJDON2 are not available.  
 
Figure 2.3: Hydrogen bonding in Protocatechuic acid monohydrate 
The crystal structure of monohydrate of PA (BIJDON3) reveals that PA forms a 
noncentrosymmetric carboxylic acid dimer; a supramolecular homosynthon (Figure 2.3 a) 
(O
…
O: 2.717 Å and 2.592 Å) and these dimers form a chain through a water molecule. 
Water molecules insert themselves between PA dimer chains forming a tetramer unit 
(b) 
(a) 
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(Figure 2.3 b). Three phenolic OH groups (two from the same PA molecule and a third 
from other PA molecule) are hydrogen bonded to water molecule and one water molecule 
is hydrogen bonded to three molecules of PA. 
 
Figure 2.4: Hydrogen bonding in Protocatechuic acid acetonitrile solvate 
In the crystal structure of the acetonitrile solvate of PA, PA forms a carboxylic 
acid dimer (O
…
O: 2.606 Å). One of the phenolic OH groups of PA is bonded to a 
phenolic OH of another pair of a PA dimer (OH
…
O: 2.688 Å) to form a zig zag chain. An 
acetonitrile molecule is trapped in between these chains via hydrogen bonding between 
nitrogen atom of acetonitrile molecule and phenol moieties of PA (OH
…
N: 2.819 Å) 
(Figure 2.4). 
 
2.2 Cocrystals of Protocatechuic acid 
Seven novel cocrystals of PA with ε-Caprolactam, Isonicotinamide, Isonicotinic 
acid (hydrated and anhydrated cocrystals), Theophylline, Nicotinamide and 
Carbamazepine are obtained. As discussed in section 2.1, carboxylic acid moiety and 
phenolic OH groups of PA are likely to form hydrogen bonds. These functional groups 
were used to form cocrystals with ε-caprolactam, isonicotinamide, isonicotinic acid, 
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theophylline, carbamazepine and nicotinamide. The summary of cocrystals synthesized is 
listed in table 2.1 
 
2.2.1 Experimental Section 
All chemicals were obtained from commercial sources and used without further 
purification. Solvents were also purchased from commercial sources and distilled before 
use. Single crystals of cocrystals 1 to 3 and 5 to 7 were obtained by slow evaporation of 
stoichiometric amounts of starting materials in an appropriate solvent as summarized in 
table 2.2 and they were removed from their mother liquors before complete evaporation 
of the solvent. Samples were characterized by powder X-ray diffraction, infrared 
spectroscopy differential scanning calorimetry, thermo gravimetric analysis (for cocrystal 
3) and single crystal X-ray data was collected for cocrystals 1-3 and 5-7. 
Table 2.1: Summary of the cocrystals of PA synthesized 
Cocrystal Target molecule 
Structure 
and Ratio 
Melting Point 
(
0
C) 
Yield 
(%) 
1 ε-Caprolactam 
Anhydrous 
(1:1) 
131  95.4 
2 Isonicotinamide 
Anhydrous 
(1:1) 
195 65.9 
3 Isonicotinic acid 
Monohydrate 
(1:1:1) 
224 62.5 
4 Isonicotinic acid 
Anhydrous 
(1:1:1) 
223 - 
5 Theophylline 
Anhydrous 
(1:1) 
254 49.5 
6 Nicotinamide 
Anhydrous 
(1:1) 
201 28.4 
7 Carbamazepine 
Anhydrous 
(1:1) 
- 89.2 
 
 
2.2.2 Cocrystallization via Solution Crystallization 
1:1 cocrystal of PA and ε-Caprolactam, 1: 
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O OH
OH
OH
MeOH + Water
C7H6O4.C6H11NO
NH
O
 
 
Figure 2.5: Synthesis and single crystal of 1 
PA (15.4 mg, 0.0999mmol) and ε-caprolactam (11.3 mg, 0.0998mmol) were 
dissolved in 1ml of methanol and 3ml of water by heating. The resulting solution was 
allowed to stand at room temperature and slowly evaporate. Colorless crystals (25.5 mg, 
0.0954 mmol, 95.5%) were harvested after 13 days and exhibited a melting point of 
131
0
C. 
1:1 cocrystal of PA and Isonicotinamide, 2: 
N
O NH2
O OH
OH
OH
MeOH + Water
C7H6O4.C6H6N2O
 
 
Figure 2.6: Synthesis and single crystal of 2 
PA (15.4 mg, 0.0999 mmol) and isonicotinamide (12.2 mg, 0.0998mmol) were 
dissolved in a mixture of 1ml of methanol and 3ml of water by heating. The resulting 
solution was allowed to slowly evaporate at room temperature. Colorless crystals of II 
(18.2 mg, 0.0659 mmol, 65.9 %) were harvested after 8 days and exhibited a melting 
point of 195
0
C. 
Monohydrate of 1:1 PA and Isonicotinic acid, 3: 
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OHO
OH
OH N
OHO
+
MeOH + H2O
C7H6O4.C6H5NO2.H2O
 
 
Figure 2.7: Synthesis and single crystal of 3 
PA (15.4 mg, 0.0999mmol) and isonicotinic acid (12.3 mg, 0. 0999 mmol) were 
dissolved in 5ml of 1:1 mixture of water and methanol by heating. The resulting solution 
was placed at room temperature and allowed to slowly evaporate. The colorless needle 
crystals (17.3, 0.0586 mmol, 62.5%) were harvested after 13 days and exhibited melting 
point of 224
0
C. 
Cocrystal of PA and Isonicotinic acid, 4: 
Cocrystal of anhydrate of protocatechuic acid and isonicotinic acid was prepared 
by dehydrating 3. Crystals of 3 were heated in an oven at 120
o
C for 48 hours thereby 
affording cocrystal 4. Unfortunately the single crystal was not harvested. The cocrystal 
exhibited a melting point of 223
0
C. 
1:1 cocrystal of PA and Theophylline, 5: 
OH
OH
OHO
N
N
N
N
CH3
H3C
O
O
H
C7H6O4.C7H8N4O2
MeOH
 
 
Figure 2.8: Synthesis and single crystal of 5 
PA (15.4 mg, 0.09mmol) and theophylline (18.0 mg, 0.09mmol) were dissolved 
in a 4ml of methanol and the resulting solution was allowed to slowly evaporate at room 
temperature. Colorless blocks of crystals of 5 (Figure 2.8) (16.5 mg, 0.0497 mmol, 
49.5%) were harvested after 3 days and exhibited a melting point of 254
0
C. 
1:1 cocrystal of PA and Nicotinamide, 6: 
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OH
O
OH
OH
N
OH
O
water slurry
Methanol
Slow evaporation
C7H6O4.C6H5NO2
 
Figure 2.9: Synthesis of 6 
PA (30.8 mg, 0.199mmol) and nicotinamide (24.4 mg, 0.199mmol) were slurried 
in a 1ml of methanol for 2 hrs and the resulting mixture was dissolved in 1ml of water 
and then allowed to slowly evaporate at room temperature. Colorless thin crystals of 6 
(15.7mg, 0.0546 mmol, 28.4%) were harvested after 7 days and exhibited a melting point 
of 201
0
C. 
Dihydrate of 1:2 cocrystal of PA and Carbamazepine, 7: 
OH
O
OH
OH
N
O
NH2
Water+Acetone
or Methanol
Slow evaporation
C7H6O4.C15H12N2O
  
 
Figure 2.10: Synthesis and single crystal of 7 
PA (15.4 mg, 0.09mmol) and carbamazepine (18.0 mg, 0.09 mmol) were 
dissolved in a 5ml of methanol and the resulting solution was allowed to slowly 
evaporate at room temperature. Colorless crystals of 7 (29.7mg, 0.0264 mmol, 89.2%) 
were harvested after 2 days. Crystals were also harvested by dissolving the starting 
materials in same quantities by heating in a mixture of water (3ml) and acetone (1ml) 
after 3 days. 
 
2.2.3 Cocrystallization via Grinding and Slurry conversion 
Attempts were made to synthesize the cocrystals using different methodologies 
described in 1.2.6. For grinding starting materials were ground in a mortar and pestle 
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using respective solvents and resulting powders were analyzed by X-ray powder 
diffraction. Also Cocrystal 5 was synthesized using an automated grinder (Retseh 
MM301 ball mill) for 90 min. The results from slurry and grinding are summarized in 
table 2.2. 
Table 2.2: Comparison of solvent evaporation, grinding and slurry techniques 
Cocrystal 
Molar ratio 
used 
Crystallization 
solvent 
Solvent for 
grinding 
Solvent for 
slurry 
1 1:1 MeOH/Water DMF Water 
2 1:1 MeOH/Water Water Water 
3 1:1 MeOH/ Water - - 
5 1:1 MeOH - Water 
6 1:1 MeOH Water Water 
7 1:1 
MeOH and 
Water/Acetone 
MeOH - 
 
 
2.2.4 FTIR, PXRD, Differential Scanning Calorimetry and Thermo   
         Gravimetric Analysis 
All samples were characterized by IR spectroscopy using a Nicolet-Avatar Smart 
Miracle 320 FT-IR instrument. The bulk samples were analyzed by X-ray powder 
diffraction. PXRD analysis was performed using a Bruker D8 ADVANCE, θ /2 θ 
diffractometer. Experimental conditions: Cu K  radiation (λ= 1.54056 Å); 50 kV and 40 
mA. Scanning interval: 3-40
0
 2 θ; time per step: 0.5 s; step size: 0.020. Thermal analysis 
was carried out using TA instrument DSC 2920 differential scanning calorimeter. 
Aluminum pans were used for the experiment for all the samples. Temperature 
calibrations were made using indium as the standard. An empty pan, sealed in the same 
way as the sample, was used as a reference. The thermograms were run at a scanning of 
10
0
C/ min from 30
0
C to the required temperature on 1-3mg of the sample. 
Thermogravimetric analysis was carried out using STM6000. Results are summarized in 
figures 2.11- 2.17. 
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Figure 2.11: Cocrystal 1: (a) PXRD comparison (b) DSC (C) IR 
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Figure 2.12: Cocrystal 2: (a) PXRD comparison (b) DSC (C) IR 
(c) 
(b) 
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Figure 2.13: Cocrystal 3: (a) PXRD comparison (b) TGA (c) DSC (d) IR 
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Figure 2.14: Cocrystal 4: (a) PXRD comparison (b) DSC (c) IR 
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Figure 2.15: Cocrystal 5: (a) PXRD comparison (b) DSC (c) IR 
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Figure 2.16: Cocrystal 6: (a) PXRD comparison (b) DSC (c) IR 
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Figure 2.17: Cocrystal 7: (a) PXRD comparison (b) TGA (c) IR (d) DSC (e) DSC 
after heating cocrystal 7 
 
 
2.2.5 Determination of Crystal Structure 
Single crystals of cocrystals 1-3 and 5-7 were examined under a microscope and 
single crystal X-ray diffraction data was collected on a Bruker-AXS SMART APEX 
CCD diffractometer with monochromatized Mo K  radiation (λ = 0.71073 Å) connected 
to a KRYO-FLEX low temperature device. 
(d) 
(e) 
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Table 2.3: Crystallographic data for cocrystals of PA
51 
 
2.2.6 Results and Discussion 
 
Figure 2.18: Each PA molecule is hydrogen bonded to three molecules of ε-
caprolactam through phenol
…
carbonyl supramolecular heterosynthon 
The crystal structure of 1 reveals that PA exists as carboxylic acid dimer [O
…
O: 
2.659(3)Å] and dimers are further connected to ε-caprolactam molecules through 
hydrogen bonding between the carbonyl moiety of PA and NH moiety of ε-caprolactam 
[NH
…
O: 2.882(3)Å] forming a heterocatemer. Each PA molecule is connected to three 
molecules of ε-caprolactam. Additional hydrogen bonding affords a three dimensional 
network. These interactions help to establish the reported interactions. 
ε-caprolactam is an organic molecule which has been listed on GRAS list. Two 
polymorphs (Refcodes: CAPLAC and CAPLAC01 and eight cocrystals are reported in 
CSD for caprolactam [Ref. codes: CAPRES (with 4-chlororesorcinol), KEWZUE (4,4'-
Biphenol), QQQGHM and QQQGHM01(with resorcinol), QQQGHP (with 
hydroquinone), QQQGHS and QQQGHS01(with 5-methylresorcinol) and QQQGHV 
(with -naphthol)]. The coordinates are not available for five of them (QQQGHM, 
QQQGHP, QQQGHS, QQQGHS01, QQQGHV). In CAPRES and KEWZUE it can be 
noted that ε-caprolactam exists as lactam dimer forming a supramolecular homosynhon 
with CO
…
HN distances 2.901 Å, 3.014 Å respectively. While in the QQQGHM01, ε-
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caprolactam in addition to the lactam dimer (CO
…
HN: 2.950 Å); supramolecular 
heterosynthon within the phenolic moiety of resorcinol and lactam (CO
…
HO: 2.665 Å 
and NH
…
O: 2.998 Å) has been also observed with lactam acting as both hydrogen bond 
donor and acceptor to a phenolic OH moiety. In the case of 1, PA breaks the lactam 
dimer forming a heterocatemer with supramolecular heterosynthon between carbonyl 
moiety of  carboxylic acid and phenolic group of PA having bond distances of NH
…
O: 
2.882(3) Å and OH
…
O: 2.736(3) Å respectively.   
Major peaks at 7.2, 9.1, 17.0, 21.1, 24.4, 25.5 and 28.0 degrees in experimental 
powder patterns matches with calculated PXRD (Figure 2.11a). The DSC shows sharp 
endotherm at 131.07
0
C (Figure 2.11 b) which falls between the melting points of the two 
starting materials (Protocatechic acid: 205
0
C Caprolactam: 68
0
C). 
 
Figure 2.19: Formation of a tape with alternate PA and isonicotinamide molecules 
by acid
…
pyridine supramolecular heterosynthon 
The single crystal X-ray structure of 2 reveals that isonicotinamide molecules 
break the PA acid dimers and forms tapes through an acid
…
pyridine [COOH
…
Narom 
(O
…
N: 2.669(10)Å)] and amide
…
phenol [N
…
O: 3.042(13)Å] supramolecular 
heterosynthons. These tapes with alternate molecules of PA and isonicotinamide are 
further connected to each other through carbonyl amide and carbonyl phenol 
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supramolecular hetersynthons [N
…
O: 3.021(13) Å and O
…
O: 2.762(10) Å]. The C-N-C 
angle of pyridine ring in isonicotinamide was observed to be 116.70
0
. 
 
Figure 2.20: One molecule of PA is hydrogen bonded to five molecules of 
isonicotinamide 
There are three entries for isonicotinamide with two polymorphs of it (EHOWIH, 
EHOWIH01 and EHOWIH02) in CSD. Recently Seaton et. al. reported monohydrate of 
isonicotinamide.
19
 Apart from this forty one cocrystals are reported till date in CSD. 
[AJAKAX (with hex-2-enoic acid), AJAKEB (with 4-nitrobenzoic acid), AJAKIF (with 
3,5-dinitrobenzoic acid and 4-methylbenzoic acid), ASAXOH (with 3-Nitrobenzoic 
acid), ASAXUN (with 4-fluorobenzoic acid), BUDWEC (with benzoic acid), BUDZUV 
(with 3,5-dinitrobenzoic acid and 3-methylbenzoic acid), BUFBIP (with 3,5-
Dinitrobenzoic acid and 4-(N,N-dimethylamino) benzoic acid), BUFQAU (with 3,5-
Dinitrobenzoic acid and 4-hydroxy-3-methoxycinnamic acid), JAWWEK (cis,cis-1,3,5-
Cyclohexanetricarboxylic acid), LUNMAI (with cinnamic acid), LUNMEM (3-
hydroxybenzoic acid), LUNMIQ (with 3-(N,N-dimethylamino) benzoic acid), 
LUNMOW (with 3,5-bis (trifluoromethyl) benzoic acid), LUNMUC (with 12-
bromododecanoic acid), LUNNAJ (with  monochloroacetic acid), LUNNEN (with 
fumaric acid monoethyl ester), LUNNIR (with 4-ketopimelic acid), LUNNOX (with 
fumaric acid), LUNNUD and LUNNUD01 (with succinic acid),  LUNPAL (d,l-mandelic 
acid), LUNPEP (with thiodiglycolic acid), MELYEI (with pyridine-2,6-dicarboxylic acid 
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and water), ULAWAF (with Oxalic acid), ULAWEJ (with malonic acid), ULAWOT and 
ULAXAG (with glutaric acid), ULAWUZ and ULAXEK (with adipic acid), VAKTOR 
(4-hydroxybenzoic acid), VAKTUX (with resorcinol), VAKVEJ (with phloroglucinol 
and water) , VAKVIN (with hydroquinone), VETVUM (with 1-Ethyl-6-fluoro-1,4-
dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid and chloroform), XAQPOV 
(with 3,5-dinitrobenzoic acid and 3,4-dimethoxycinnamic acid), XAQQEM (with 2-
hydroxybenzoic acid), ULAWAF01(with cis-oxalic acid), ULAWAF02 (with trans-
oxalic acid), YIPCEG (with iodine) and YIPCIK (with p-tetrafluorodi-iodobenzene). 
Among these structures 35 of them are with carboxylic acids. The crystal 
structures of 34 form acid
…
pyridine supramolecular heterosynthon with exception of one 
(VAKTOR) having carboxylic acid
…
amide and phenol
…
pyridine supramolecular 
heterosynthons. In accordance with these observations as predicted this dominant acid-
pyridine supramolecular heterosynthon was observed in case of 2.  
The C-N-C angle in aromatic nitrogen moieties are known to be sensitive to 
protonation.
7
 Also the geometrical features of carboxylic acid and carboxylate are known 
to be different.
8
 Thus examination of quantitative differences such as C-N-C angle of 
pyridine to protonation at nitrogen and distinction in C
…
O bond lengths between 
carboxylate and carboxylic acid will further provide an information whether 2 is a 
cocrystal or a salt.
9
 
If the proton transfer from a carboxylic acid to base i.e pyridyl nitrogen in the 
case of 2, which lead to formation of a salt, takes place, the carboxylate ion shows the 
same bond distance for C
…
O. In the case of cocrystal formation, bond lengths of C
…
O 
and C
…
OH differ which is observed in 2; the distances are 1.222 Å and 1.323 Å. 
From table 2.4 it has been observed that C-N-C angle in 41 cocrystals of 
isonicotinamide with 35 carboxylic acids, 1 zwitterion, 3 phenols and 2 halogenated 
molecules is in the range of 116.90 to 119.91
0
. The C-N-C angle in 2 is 116.70
0
 which 
can be correlated with the observed range supporting the neutral nature of 
isonicotinamide in the structure.  
The difference in pKa of aromatic nitrogen base and carboxylic acid is used as an  
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indicator to conclude whether it‟s a salt or neutral bond or proton transfer results. In 
pharmaceutical industry pKa difference greater that 2 or 3 are used for salt formation.
10
 
ΔpKa= pKa(base)-pKa(acid) for 2 is -1.06 which suggests the formation of neutral bond. 
Hence in 2; pyridine nitrogen is not protonated giving rise to formation of neutral 
cocrystal and not a salt. Solution NMR is also a useful technique to conclude whether it is 
a salt or cocrystal.  
PXRD comparison shows major peaks are present in the experimental powder x-
ray diffraction pattern at 16.0, 18.1, 24.6, 25.7, 26.7, 29.3, 29.6 and 31.5
0
 2  positions 
match with the calculated powder pattern (Figure 2.12 a). Also powder pattern from 
water slurry shows the formation of cocrystal. DSC shows a sharp endotherm at 195.29
0
C 
(Figure 2.12 b) which falls in between the melting points of starting materials (PA: 
205
0
C; Isonicotinamide: 155-157
0
C). 
Table 2.4: C-N-C angles in neutral isonicotinamide cocrystals from CSD 
Refcode 
C-N-C angle 
(
0
) 
Refcode 
C-N-C angle 
(
0
) 
Refcode 
C-N-C 
angle (
0
) 
AJAKAX 117.60 LUNMUC 117.16 ULAXAG 117.35 
AJAKEB 118.63 LUNNAJ 119.15 ULAXEK 118.22 
AJAKIF 117.68 LUNNEN 118.19 VAKTOR 116.90 
ASAXOH 117.29 LUNNIR 117.69 VAKTUX 
117.48 
117.60 
ASAXUN 117.03 LUNNOX 118.24 VAKVEJ 
117.29 
117.63 
BUDWEK 117.68 LUNNUD 117.58 VAKVIN 117.33 
BUDZUV 117.69 LUNNUD01 118.01 VETVUM 115.88 
BUFBIP 117.66 LUNPAL 117.46 XAQPOV 117.39 
BUFQAU 118.46 LUNPEP 
117.46 
118.28 
XAQQEM 117.86 
JAWWEK 
116.86 
117.35 
MELYEI 117.35 ULAWAF01 119.67 
LUNMAI 117.86 ULAWAF 119.47 ULAWAF02 119.91 
LUNMEM 118.18 ULAWEJ 
118.62 
119.02 
119.37 
119.48 
120.58 
ULAWUZ 118.05 
LUNMIQ 117.25 ULAWOT 
117.38 
117.55 
LUNMOW 117.74 
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Figure 2.21: PA molecules forming acid-acid supramolecular homosynthon 
and supramolecular heterosynthons with two water molecules and one isonicotinic 
acid molecule. 
The single crystal X-ray analysis of 3 shows PA molecule exist as a carboxylic 
acid dimer [O-H
…
O: 2.616(6) Å] and isonicotinic acid molecules exist as zwitterions. 
One of the phenolic group of PA is hydrogen bonded to the isonicotinic acid through 
water molecule [H2O
…
OH: 2.621(5) Å] and the remaining phenolic moiety is hydrogen 
bonded to isonicotinic acid [O-H
…
O: 2.706(6) Å]. PA molecules forms dimers and 
isonicotinic acid molecules form a chain hanging out to either side of protocatechuic acid 
dimers (Figure 2.22). The zwitterionic nature of isonicotinic acid molecule is supported 
by C-N-C angle of 121.50
0
 in pyridine ring.  
 
Figure 2.22: Formation of isonicotinic acid chains in 3 
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An analysis of the CSD shows no cocrystals of isonicotinic acid. But the crystal  
structure of neutral isonicotinic acid is known in CSD with ref. code ISNICA. Also there 
are five entries involving isonicotinate ion. [AJECAT (with 3,5-dinitrosalicylate), 
FETXIM (4-Aminopyridinium and water), REFFIS (with R-1,1'-binaphthalene-2,2'-diyl-
phosphate), XECDUF and XECDUF01 (with chloride) and YERXUP (with  2,5-
dichloro-4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-olate and water)]. Based on these 
observations Zaworotko et. al recently published that the COOH
…
Narom supramolecular 
heterosynthon that would be expected if a cocrystal were to form.
11
 This expected 
supramolecular synthon is present in cocrystal 3. Further whether 3 is a salt or a 
zwitterionic cocrystal can be distinguished as explained in the case of 2; by the 
examination of C-N-C angle and the location of proton by C
…
O distances in carboxylate 
and carboxylic acid. 
The C-N-C angle of 3 supports the non existence of neutral isonicotinic acid 
molecule since the C-N-C angle in neutral isonicotinic acid is 118.91
0
. The salt is an 
ionic species whereas zwitterion is a species which carries a total net charge of zero but 
carries formal positive and negative charges on different atoms within the molecule. In 3, 
examination of bond lengths in carboxylic acid moiety (C
…
O: 1.224 Å and 1.259 Å) 
resulted the presence of carboxylate ion. This carboxylate carrying formal negative 
charge and  pyridyl nitrogen of isonicotinic acid carrying a formal positive charge 
because of a proton transfer gives rise to overall neutral molecule. Hence 3 is a 
zwiterionic cocrystal. 
The major peaks at 13.3, 17.3, 19.1, 22.9, 23.8, 25.2, 27.8 and 39.3
o
 from the 
experimental powder x-ray diffraction pattern (Figure 2.13 a) matches with the calculated 
powder pattern. DSC shows three endotherms (Figure 2.13 c). The endotherm at 
115.10
0
C corresponds to solvent molecule which is a water molecule and endotherm at 
224.20
0
C corresponds to cocrystal of anhydrate. The third endotherm around 300
0
C may 
correspond to the decomposition of isonicotinic acid. TGA (Figure 2.13 b) supports the 
loss of water molecule (5.24%) which correlates the calculated % loss (6.09%). 
Attempts to obtain single crystal of 4 were unsuccessful. But the powder X-ray 
diffraction data after heating 3 shows the formation of new cocrystal (Figure 2.14 a) 
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which is well supported by DSC. The absence of first endotherm from 3 shows the 
absence of water molecule in the 4. Also endotherm at 223.19
0
C correlates with the 
endotherm present in 3.  
 
Figure 2.23: Acid dimer of PA molecules forming supramolecular 
heterosynthon with theophylline dimers 
The single crystal X-ray crystallographic study analysis of 5 reveals that PA 
forms a acid dimer [O-H---O: 2.636(19) Å] and theophylline form dimers with  
N-H
…
O=C contacts at a distance of 2.781(2) Å. The two remaining phenolic groups form 
PA hydrogen bonds with theophylline molecules through OH---O=C [2.703(17) Å] and 
OH---N contacts [2.774(2) Å] to establish an overall sheet structure. Each PA molecule is 
hydrogen bonded to two theophylline molecules through phenolic OH moieties (Figure 
2.23).  
Theophylline is a naturally occurring drug (present in tea) used in the treatment of 
respiratory diseases such as asthma. The crystal structure of anhydrous and monohydrate 
of theophylline as well as number of cocrystals have been reported to date in CSD 
[Reference codes: CSATEO (with 5-chlorosalicylic acid); DUXZAX(with urea); 
SULTHE (with sulfathiazole); THOPBA (with phenobarbital);TOPPNP (with p-
nitrophenol);WUYROX (with N-(2-aminoethyl)-carbamate); XEJWUF (with oxalic 
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acid); XEJXAM (with malonic acid), XEJXEQ (with maleic acid); XEJXIU (with 
glutaric acid); ZAYLOA (with 5-fluorouracil and water) and ZEXTIF (with p-
nitroaniline); KIGKAN (with citric acid and water); KIGLAO (with sorbic acid); 
KIGLES (with salicylic acid); KIGLIW (with 1-hydroxy 2-napthoic acid); KIGLOC 
(with 4-hydroxy benzoic acid); KIGLUI (with N-(4-hydroxyphenyl)acetamide); 
XOBCUN (with saccharin)]. In theophylline there are three sites of hydrogen bond 
acceptor and also one site of hydrogen bond donor. Out of 23 cocrystals 9 of them shows 
theophylline dimers in the crystal structure. In 5 it can be observed that this dimer as well 
as phenol
…
imidazole and phenol
…
carbonyl supramolecular heterosynthon is present. 
 
Figure 2.24: Formation of sheets in 5 
PXRD of experimental pattern shows major peaks at 11.6, 15.8, 22.8, 25.2 and 
27.3
o
 which are present in the calculated powder x-ray diffraction pattern (Figure 2.15 a). 
The sharp endotherm in DSC (Figure 2.15 b) at 254.28
0
C falls in between the melting 
points of the starting materials (PA: 205
0
C; Theophylline: 274
0
C). 
The single crystal X-ray studies of 6 reveals that PA and nicotinamide forms an  
acid amide dimer [N
…
O: 2.875(18) Å and O
…
O: 2.639(17) Å]. One unit of dimer is 
hydrogen bonded to other in helical fashion in which amide moiety is hydrogen bonded 
to carbonyl moiety of PA [N
…
O: 2.990(2)Å]. Also aromatic pyridine nitrogen of 
nicotinamide hydrogen bonds to phenolic OH of PA [Narom
…
O: 2.671(17) Å] to form the 
helix. Dimer units in the helix create pi-pi stacking (centroid to centroid distance 3.750 
Å). Nicotinamide is a small molecule of vitamin B family. Nicotinamide serves as a 
target molecule because of its high medicinal value such as anti-anxiety,
12
 anti 
inflammatory
13
 and in Alzheimer‟s disease.14 Two polymorphs of nicotinamide are 
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known in CSD with three entries (Refcodes: NICOAM01, NICOAM02, NICOAM03).  
There are eleven cocrystals of nicotinamide are reported in CSD till date. FIFLAI, 
UCOTUC, VIGDAR, IACNCA, JEMDIP, PEQBES, UNEZES, XAQPUB, XAQQIQ, 
CIPHAL, JILZOU. 
 
Figure 2.25:  One molecule of PA is hydrogen bonded to two molecules of PA 
through OH
…
OH supramolecular homosynthon, one molecule of nicotinamide 
through acid
…
amide supramolecular heterosynthon and with another nicotinamide 
molecule through OH
…
NH2 supramolecular heterosynthon 
Among 11 cocrystals; 8 of them are with carboxylic acid and in these 8 cocrystal 
1 is phenolic acid. Except XAQQIQ in rest all 7 cocrystals carboxylic acid-pyridin 
supramolecular heterosynthon was observed. XAQQIQ exhibits carboxylic acid-primary 
amide and phenol-pyridine supramolecular heterosynthon. This was expected in the case 
of 6 and observed the same. The C-N-C angle for nicotinamide cocrystals are 
summarized in table 2.5, which shows the range of 116.81 to 118.25. In case of 6 the 
observed C-N-C angle is 120.39 which still falls in the neutral range of C-N-C angle. 
ΔpKa of nicotinamide and protocatechuic acid is –0.91 which supports the formation of 
neutral bond as explained in case of 2. 
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Table 2.5: C-N-C angles in neutral nicotinamide cocrystals from CSD 
 
 
Figure 2.26: Overall packing of 6 
 The majors peaks at 8.4, 11.5, 16.7and 19.2 
o
 from the experimental PXRD data 
matches with the calculated PXRD pattern (Figure 2.16a). DSC shows the sharp 
endotherm at 200
0
C (Figure 2.16b)which falls in between the melting points of starting 
material (PA: 205
0
C and nicotinamide: 128-131
0
C).  
 
Figure 2.27: Chain of disordered PA and water molecules hydrogen bonding with 
carbamazepine dimers  
Refcode 
C-N-C angle 
(
0
) 
Refcode 
C-N-C angle 
(
0
) 
Refcode 
C-N-C angle 
(
0
) 
FIFLAI 117.98 PEQBES 118.00 XAQQIQ 117.39 
IACNCA 117.44 UCOTUC 116.81 JILZOU 
118.25 
118.42 
JEMDIP 117.05 XAQPUB 117.47   
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 In single crystal analysis of dihydrate of PA, carbamazepine cocrystal; PA is not 
very well defined in the structure. The reason can be disorder or twinning in the crystal. 
Model of the disorder shows that PA forms chins with water molecules and hydrogen 
bonded to carbamazepine dimers. R factor is approximately 5% so model can be reliable. 
Structure can solved in lower space group but can not be refined very well. 
 
2.3 Dissolution Studies 
To address solubility, dissolution and other physicochemical properties; 
cocrystals have come up with a promising future as explained in section 1.2.4. Having 
understood the importance of it, the efforts are underway to correlate the solubility and 
stability of a cocrystal with properties of pure components and if one can predict the 
trend in solubility. To concentrate on this issue Rodrı´guez-Hornedo et.al has recently 
published the study of 25 cocrystals of carbamazepine with their dissolution data and 
they have concluded that (1) solubility increases with the solubility of  cocrystal 
components, (2) ligand transition concentrations increase with cocrystal and ligand 
solubilities for cocrystals of the same drug, and (3) ligand solubility about 10-fold higher 
than drug leads to cocrystal being more soluble than drug.
15
  
 For further contribution to this regard dissolution studies of cocrystals of PA have 
been carried out. In formulating and controlling the drug quality, dissolution is commonly 
used technique in pharmaceutical industries.
 16
 The common analytical methods used for 
the quantification in dissolution studies are mainly spectrophotometric, chromatographic, 
mass spectrometric and potentiometric. 
17
 UV/VIS spectrophotometry is the most 
prominent method. Cocrystals 1, 2 and 5,6 are chosen for the dissolution studies. Water 
solutions of all cocrystals show absorption band in UV/VIS. The dissolution studies are 
carried out with respect to PA and 310 nm was chosen to be the common wavelength for 
all cocrystals where absorption of cocrystal formers does not interfere with the absorption 
of PA. As kinetic dissolution is influenced by particle size distribution and experimental 
apparatus, all the cocrystals were sieved using ASTM standard sieve to obtain particle 
sizes between 53-75 m. All the experiments were carried out at room temperature and in 
set of three for the reliability under constant and same stirring speed. Calibration curves 
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are determined in set of three with seven varying dilutions. Approximately 80-100 ml of 
water was used and an aliquot was drawn from the resulting slurry of cocrystal at regular 
time intervals using a syringe. The filtrate (use of 0.25 m nylon filter) was diluted with 
water and UV absorption was recorded. Results are plotted as concentration (mg/ml) 
versus time (min) and are summarized in figure 2.28. 
 It has been observed that apart from cocrystal 1 all other cocrystals 2, 4, and 5 
lower the solubility of PA. The solubility of cocrystal formers is in the order of 
caprolactam > nicotinamide > isonicotinamide > theophylline. Solubility of theophylline 
is less than the pure PA and all others are having higher solubility than PA. It was 
observed based on Rodrı´guez-Hornedo et.al. studies15 as the solubility of cocrystal 
former increases the solubility of cocrystal increases and thus cocrystals 1,2 and 6 should 
increase PA solubility and 5 should decrease the solubility of PA. As predicted 1 showed 
an increase in solubility of PA about one and half fold and 5 showed about four fold 
decrease in solubility of PA. But 2 and 6 are the outliners. As per the assumption as 
isonicotinamide and nicotinamide are more soluble cocrystal formers and furthermore 
nicotinamide has higher solubility than isonicotinamide, 6 predicted to be higher in 
dissolution profile than 2 and PA. The observed data is contradictory to the assumptions 
and thus cocrystals afford solubility in unpredictable manner. 
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Figure 2.28: Comparison of dissolution profiles of PA and its cocrystals 
 To correlate dissolution profiles the detail comparison of crystal packing was 
carried out. As shown in figure 2.16 and 2.20 acid-acid dimer of PA is intact while in 
case of 2 and 6 as shown in figures 2.17 and 2.22 acid dimer is interrupted and acid-
pyridine and acid-amide supramolecular heterosynthons are observed respectively. 
Furthermore isonicotinamide and nicotinamide cocrystals show pi stacking (Figure 2.29) 
that may be increasing the lattice energy causing lower solubility. Pi stacking is stronger 
in 6 than 2.  
Another observation is, as solubility decreases melting point of cocrystal 
increases. Melting temperatures of pharmaceutical crystals have been found an important 
indicator in solubility prediction. In structurally similar pharmaceutical crystalline drugs, 
high melting drugs are generally recognized to possess lower solubility.
18
 Even though it 
is generally expected that solubility and melting points are correlated it has not been 
observed in case of study of carbamazepine cocrystals.
15 
Dissolution profiles of cocrystals also suggest the thermodynamic stability of the 
cocrystals. In conclusion PA as a small molecule has altered the solubility of its 
cocrystals with caprolactam, isonicotinamide, nicotinamide and thophylline. The trend of 
the solubility is independent of the solubility of a cocrystal former in case of PA since 
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direct proportionality was not observed. But it correlates with melting temperature of a 
cocrystal and higher temperature lowers the solubility. 
                    
Figure 2.29: Pi stacking in (a) PA nicotinamide (b) PA isonicotinamide cocrystals 
In conclusion, seven novel cocrystals of PA have been developed using the 
strategies of crystal engineering. The OH
…
OH supramolecular homosynthon has been 
defeated by supramolecular heterosynthon in all cocrystals. As per the CSD statistics 
phenol
…
pyridine supramolecular heterosynthon is more reliable than phenol
…
phenol 
supramolecular homosynthon and it has been seen in cocrystals of PA-nicotinamide. But 
in case of cocrystals of PA with isonicotinamide and isonicotinic acid
...
pyrine 
supramolecular heterosynthon overcomes the phenol
…
pyridine supramolecular 
homosynthon as reported in case of competition of supramolecular synthons when both 
COOH and OH moieties are present with aromatic nitrogen base.
11
 In isonicotinamide, 
isonicotinic acid and nicotinamide molecules aromatic nitrogen acts as a free base and 
accepts hydrogen from phenol or acid moiety. Theophylline has a tendency to form dimer 
leaving carbonyl as hydrogen accepter which has been also observed in case of PA-
theophylline cocrystal. Furthermore dissolution studies of cocrystals shows an alteration 
in solubility of PA with the formation of cocrystal. The solubility of a cocrystal is 
irrespective of the solubility of the cocrystal former. 
 
(b) (a) 
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3. Quercetin 
3.1 Introduction 
 
Figure 3.1: Structure of Quercetin 
Flavonoids are a group of phenolic plant compounds which are secondary 
metabolites of plant.
1
 To date, more than 6000 flavonoids have been identified.
2
 They are 
present in most edible fruits and vegetables, but the type of flavonoids obtained from 
different dietary sources varies.
 3
 Flavonoids and flavonoid containing products have 
been reported to possess biological activities.
4
 Flavonoids are divided into several 
subgroups. They consist of 2 benzene rings (A and B), which are connected by an oxygen 
containing pyrene ring (C). Flavonoids containing a hydroxyl group in position C-3 of the 
C ring are classified as 3-hydroxyflavonoids e.g. flavonols and those lacking it as 3-
deoxyflavonoids e.g. flavanones and flavones. 
Quercetin (3,4,7,3‟,4‟-pentahydroxyflavanone, C15H10O7, Mol.Wt. 302.326, 
M.P.316
0
C) is one of the most prevalent flavonol  present in health food. Several studies 
have been carried out on the daily intake of quercetin in different countries and the 
importance of different foods in quercetin sources. Hertog et. al. concluded that wine was 
the major source of quercetin in Italy, while onion and apples contributed most in the 
United States, Finland, Greece, and former Yugoslavia.
5
 Recently Hakkinen et. al. 
estimated that onions, followed by tea, apples, and berries are the major sources of 
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quercetin in Finland. Besides its antioxidative and anticancer properties, quercetin also 
has been reported to benefit prostatitis and interstitial cystitis 
6, 7
. Thus quercetin can be 
viewed as a promising pharmacological agent because of the popular usage of products 
containing quercetin. According to BCS classification quercetin is a low soluble (0.45g/l) 
molecule. The bioavailability of quercetin is 5.3% in rats and LD50 is 163 mg/kg.
8
 This 
low solubility and bioavailability limits the usage of quercetin. As explained in section 
1.2.4; cocrlystallization can alter the solubility and bioavailability of the target molecule. 
The study herein focuses to synthesize cocrystals of quercetin to improve its solubility 
and thus bioavailability.  
Quercetin contains four phenolic OH groups and one hydroxyl group which can 
act acceptor/donor and one carbonyl and one ether moiety which can act as a hydrogen 
bond acceptor. Based on the CSD search as discussed in section 1. 4.2 for the occurrence 
of supramolecular synthons between polyphenols and other functionalities, aromatic 
nitrogen, carbonyls and amides would be promising. Thus different cocrystal formers 
were selected on the basis of their solubility, toxicity, pKa and cost as summarized in 
tables 1. 3, 1.4 and 1.5. 
 
3.1.1 Quercetin in CSD 
To date, the crystal structure of pure quercetin is not known but CSD contains two 
entries for quercetin dihydrate (Ref. codes: FEFBEX, FEFBEX01).  
In the crystal packing of quercetin dihydrate quercetin exists as dimer through 
phenolic OH
…
carbonyl sypramolecular heterosynthon. These two functionalities form 
intermolecular hydrogen bonding too within the quercetin molecule. This quercetin 
dimers are hydrogen bonded to other dimers through water molecule. This extended 
hydrogen bonding network forms a sheet structure. 
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Figure 3.2: OH
…
carbonyl supramolecular heterosynthon in quercetin dihydrate  
 
Figure 3.3: Intermolecular interactions in the 1:1:1 cocrystal solvate of quercetin, 
caffeine and methanol 
 Apart from the CSD entries, Zaworotko et.al patented three cocrystals of 
quercetin; 1:1:1 cocrystal of quercetin, caffeine and methanol, 1:1 cocrystal of quercetin 
and isonicotinamide and de-solvated cocrystal of quercetin and caffeine.
9
 The single 
crystal analysis for de-solvated cocrystal of quercetin-caffeine is not available. The 
crystal structure of cocrystal of methanol solvate of quercetin and caffeine shows that 
caffeine interacts with quercetin molecule through phenolic OH
…
Narom (2.831 A
o
) and  
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OH
…
O=C (2.716 A
o
) supramolecular heterosynthon. Another carbonyl of caffeine 
molecule hydrogen bonds to methanol molecule (OH
…
O: 2.712 Å). Quercetin molecules 
hydrogen bonds with each other via OH
…
OH (2.774 Å, 2.847 Å) supramolecular 
homosynthon. Overall it forms stacked sheets.  
 The crystal structure of quercetin and isonicotinamide shows that quercetin and 
isonicotinamide forms a four component assembly composed of two phenolic OH
…
O=C 
(from isonicotinamide) (2.607 Å) supramolecular heterosynthon and two NH
…
OH (3.028 
Å) supramolecular heterosynthons. Quercetin molecule forms a dimer with OH
…
OH 
(2.765 Å) supramolecular homosynthon.  
 
Figure 3.4: Intermolecular interactions in the 1:1 Quercetin-Isonicotinamide 
cocrystal 
 
3.2 Cocrystals of quercetin 
Two novel cocrystals of quercetin with isonicotinic acid and theobromine were 
prepared. As discussed in 3.1 phenolic OH groups and carbonyl group were utilized to 
form a cocrystal with the functional groups from isonicotinic acid and theobromine. The 
summary of cocrystals synthesized is listed in table 3.1. 
 
3.2.1 Experimental Section 
All the chemicals were obtained from commercial sources and used without 
further purification. Solvents were also purchased from commercial sources and distilled 
before use. The single crystals of cocrystals 1 and 2 were obtained by slow evaporation of 
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stoichiometric amounts of starting materials in an appropriate solvent as summarized in 
table 3.2, and they were removed from their mother liquors before complete evaporation 
of the solvent had occurred. All samples were characterized by powder X-ray diffraction, 
infrared spectroscopy, differential scanning calorimetry, thermogravimetric analysis and 
single crystal X-ray diffraction. 
Table 3.1: Summary of cocrystals of quercetin obtained 
Cocrystal Target molecule 
Structure 
and Ratio 
Melting Point 
(
0
C) 
Yield 
(%) 
1 Isonicotinic acid 
Monohydrate 
(1:1:1) 
283 95.5 
2 Theobromine 
Dihydrate 
 (1:1:2) 
294 65.9 
 
 
3.2.2 Cocrystallization via Solution Crystallization 
1:1:1 cocrystal of quercetin, isonicotinic acid and water 1: 
O
O
OH
OH
OH
OH
HO
.2H2O
N
OH
O
Acetone + Methanol
C15H10O7. 
C6H6NO2.H2O
  
Figure 3.5: Synthesis and single crystal of 1 
Quercetin dihydrate (33.8 mg, 0.0999 mmol) was dissolved in 10ml of acetone 
and isonicotinic acid (12.3 mg, 0.0999 mmol) was dissolved in 2mL of water by heating 
on a hotplate. The resulting solutions were filtered together and placed in a refrigerator to 
slowly evaporate. After 8 days yellow plate crystals of 1 (26.4mg, 0.0595 mmol, 95.5%) 
were obtained and exhibited a melting point of 283
0
C. 
1:1:2 cocrystal of quercetin, theobromine and water 2: 
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O
O
OH
OH
OH
OH
HO
2H2O
N
N
N
N
O
O
CH3
CH3
Ethanol+ Water
C5H10O7.C7H8N4O2.2H2O   
Figure 3.6: Synthesis and single crystal of 2 
Quercetin dihydrate (33.8 mg, 0.0999 mmol) and theobromine (18.0 mg, 0. 
0999mmol) were dissolved in 5 ml of ethanol and 10ml of 1:1 mixture of water and 
ethanol respectively by heating. Resulting solutions were filtered together and placed in 
the refrigerator for slow evaporation. The crystals of 2 (18.2mg, 0.0351mmole, 65.9%) 
were harvested after 4 days and exhibited a melting point of 294
0
C. 
 
3.2.3 Cocrystallization via Grinding and Slurry conversion 
 Using different methodologies attempts were made to synthesize the cocrystal as 
described in section 1.2.6. Only cocrystal 2 was successfully obtained by grinding as well 
as slurry conversion.  
Table 3.2: Comparison of solvent evaporation, grinding and slurry techniques 
Cocrystal 
Molar ratio 
used 
Crystallization 
solvent 
Solvent for 
grinding 
Solvent for 
slurry 
1 1:1 MeOH/Water - - 
2 1:1 EtOH/Water Ethanol Ethanol 
 
 
3.2.4 FTIR, PXRD, Differential Scanning Calorimetry and   
         Thermo Gravimetric Analysis 
All samples were characterized by IR spectroscopy using a Nicolet-Avatar Smart 
Miracle 320 FT-IR instrument. The bulk samples were analyzed by X-ray powder 
diffraction. PXRD analysis was performed using a Bruker D8 ADVANCE, θ /2 θ 
difractometer. Experimental conditions: Cu K  radiation (λ= 1.54056 Å); 50 kV and 40 
mA. Scanning interval: 3-40
0
 2 θ; time per step: 0.5 s; step size: 0.020. Thermal analysis 
was carried out using a TA instruments DSC 2920 differential scanning calorimeter. 
Aluminum pans were used for the experiment for all the samples. Temperature 
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calibrations were made using indium as the standard. An empty pan, sealed in the same 
way as the sample, was used as a reference. The thermograms were run at a scanning of 
10
0
C/ min from 30
0
C to the required temperature on 1-3mg of the sample. Results are  
summarized in figures 3.7 and 3.8.  
 
 
 
0 5 10 15 20 25 30 35 40 45
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Quercetin_Isonicotinic acid_expt(298k)
Quercetin_Isonicotinic acid_cal(100k)
R
e
la
ti
v
e
 I
n
te
n
si
ty
2  degree
(a) 
(b) 
75 
 
 
 
 
 
Figure 3.7: Cocrystal 1: (a) PXRD comparison (b) TGA (c) DSC (d) IR 
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Figure 3.8: Cocrystal 2: (a) PXRD comparison (b) TGA (c) DSC (d) IR 
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3.2.5 Determination of Crystal Structure 
Single crystals of cocrystals 1 and 2 were examined under a microscope and 
single crystal X-ray diffraction data were collected on a Bruker-AXS SMART APEX 
CCD diffractometer with monochromatized Mo K  radiation (λ = 0.71073 Å) connected 
to a KRYO-FLEX low temperature device. 
Table 3.3: Crystallographic data for cocrystals of quercetin 
 Cocrystal 1 Cocrystal 2 
Formula C21 H17 N O10 C22 H22N4O11 
MW 443.36 518.44 
Crystal System Monoclinic Triclinic 
Space group C2/c P-1 
a (Å) 34.7256(4) Å 7.0110(4) 
b (Å) 7.43960(10) Å 11.2992(5) 
c (Å) 14.3727(2) 14.9618(7) 
(deg) 90° 106.548(3) 
(deg) 90.07° 101.816(3) 
(deg) 90° 94.797(3) 
V /(Å
3
) 3713.11(8) 1099.29(9) 
Dc/ mgcm
-3
 1.586 1.566 
Z 8 2 
Z‟ 1 1 
2  range 2.54 to 67.41 3.17 to 67.25 
Nref./Npara. 3207 /  357 3641 / 422 
T /K 100(2) 293(2) 
R1 [I>2sigma(I)] 0.0369 0.0430 
wR2 0.0896 0.1039 
GOF 1.047 1.028 
Abs coef./mm
-1
 1.102 1.097 
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3.2.6 Results and Discussion 
 
Figure 3.9: Quercetin dimers hydrogen bonding with isonicotinic acid molecules 
through phenol
…
carboxylate supramolcular heterosynthon 
The single crystal X-ray analysis of 1 reveals that quercetin molecules form 
dimers through hydroxyl-carbonyl (OH
…
O=C) supramolecular homosynthon. Phenolic 
OHb moiety forms an intermolecular hydrogen bond with the carbonyl functionality. 
Phenolic OHe is hydrogen bonding to water molecule.  And remaining two phenolic OH 
groups from ring A and ring B are engaged in hydrogen bonding with one molecule  of 
isonicotinic acid which are in zwiterionic forms and one molecule of water. Thus each 
quercetin molecule is hydrogen bonded to three molecules of water, one molecule of 
quercetin and two molecules of isonicotinic acid (Figure 3.9).  Isonicotinic acid forms a 
chain with expected acid-pyridine supramolecular heterosynthon (Figure 3.10). As 
expected from the CSD statistics explained in 1.4.2 acid-pyridine supramolecular 
heterosynthon was observed and quercetin dimer is intact. 
As explained in section 2.2.6 for cocrystal 3 (cocrystal of PA with isonicotinic 
acid), examination of C-N-C angle and location of a proton will distinguish 1 from a 
neutral cocrystal or a salt or a zwitreionic cocrystal. The C-N-C angle of 121.70
0
 suggests 
the non existence of neutral isonicotinic acid molecule in comparison with the C-N-C 
angle is neutral isonicotinic acid molecule (118.91
0
). The location of the proton can be 
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confirmed by the C
…
O distances in carboxylate and in carboxylic acid. In 1, examination 
of these bond lengths resulted in the presence of carboxylate ion (C
…
O: 1.244 Å and 
1.263 Å) where as in case of neutral isonicotinic acid molecule these distances are 1.215 
Å and 1.294 Å. Furthermore both the formal charges are present on the same molecule 
resulting a overall neutral species. Thus 1 is zwiterionic cocrystal and not a salt. 
 
Figure 3.10: Formation of a chain of isonicotinic acid molecules with acid-
pyridin supramolecular heterosynthon 
The major peaks at 5.1, 10.3, 12.2, 13.3, 15.3, 20.5, 24.4 and 30.8
o
 from the 
experimental powder x-ray diffraction pattern (Figure 3.7 a) matches with the calculated 
powder pattern. DSC shows three endotherms (Figure 3.7 c). The endotherm at 196.17
0
C 
corresponds to solvent molecule which is a water molecule and endotherm at 282.68
0
C is 
corresponding to cocrystal of anhydrate. The third endotherm around 320
0
C may be 
corresponding to the decomposition of isonicotinic acid and quercetin as well. TGA 
(Figure 3.7 b) supports the loss of water molecule (4.85%) which correlates the 
calculated % loss (4.05%). 
Attempts to dehydrate 1 by heating in vacuum oven were carried out. DSC 
showed disappearance of the endotherms at 196
0
C and 283
0
C but the endotherm of 
decomposition temperature of quercetin and isonicotinic acid was present. Cocrystal 
components might be falling apart from each other and decomposing individually. 
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Figure 3.11: DSC after heating cocrystal 1  
 
Figure 3.12: Quercetin dimer hydrogen bonding with one theobromine molecule 
through carbonyl-phenol supramolecular heterosynthon 
The single crystal X-ray crystallographic study analysis of 2 reveals that quercetin 
molecules exist as a dimer through hydroxyl-carbonyl [OH
…
O: 2.616(2) A
0
] 
supramolecular homosynthon. These dimers are further hydrogen bonding to 
theobromine dimers [CO
…
HN: 1.916 A
0
] via phenol-carbonyl (OH
…
O: 2.752(2)A
0
) 
supramolecular heterosynthon from one side and through water molecule from other side. 
The remaining phenolic group is hydrogen bonded to Narom of theobromine through water 
molecule (OH
…
OH: 2.796 A
0
 and H2O
…
Narom:2.822(3) A
0
]. Overall it forms a sheet. 
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Adjacent sheets are linked to each other through water molecule to give an overall 3D 
network (Figure 3.13). 
 
Figure 3.13: Formation of sheet structure in 2 
Theobromine is a molecule from xanthine family and a major constituent of 
chocolate. Theobromine is a bitter alkaloid of cacao plant. The name theobromine is 
derived from theobroma meaning food of the gods in Greek. The use of theobromine in 
cancer has been patented
10
 and currently theobromine is used as a vasodilator, diuretic 
and heart stimulant.
11
 The crystal structure for pure theobromine is known in CSD (Ref. 
code: SEDNAQ). It reveals that theobromine molecules form dimer through amide-amide 
supramolecular homosynthon. Apart from the pure structure two cocrystals [Ref. code: 
CSATBR (with 5-chlorosalicylic acid) and HIJYEF (malonic acid)] are known. In both 
the cocrystals it can be observed that theobromine forms acid
…
 amide dimer and 
imidazolyl nitrogen acts as a hydrogen bond acceptor and forms supramolecular synthon 
with respective carboxylic acid OH moiety.  
In case of 2 theobromine amide dimer is observed and imidazolyl nitrogen acts as 
hydrogen acceptor through supramolecular heterosynthon with water molecule. Carbonyl 
functionality of theobromine forms supramolecular heterosynthon with phenolic OHa of 
quercetin which correlates with CSD statistics explained in 1.4.2. Attempts to synthesize 
the anhydrous cocrystal of theobromine were made. The cocrystal was heated in vacuum 
oven at 120
0
C for 3 hours. DSC showed dehydrated product. When PXRD pattern of 2 
and dehydrated product was compared it was observed that all the peaks from the 2 were 
present but shifted to left in dehydrated product. After 30 min. TGA was recorded and it 
was observed that cocrystal contains 1.1% of water. It can be concluded that cocrystal 
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might not be stable and during the course of the investigation cocrystal absorbs water 
from air giving a hydrated product. 
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Figure 3.14: (a) PXRD pattern (b) DSC (C) TGA of attempts of synthesizing 
anhydrous cocrystal of 2 
 
3.3 Dissolution Studies 
Low solubility and bioavailability limits the use of quercetin as a therapeutic 
target molecule. The dissolution studies of cocrystals of quercetin with isonicotinamide 
and caffeine methanol solvate are already patented and it has been shown the six fold 
increase in solubility of quercetin in both the cases.
9
 Furthermore de-solvated cocrystal of 
quercetin-caffeine shows 21 fold increase. Also in case PA molecule; as explained in 
section 4.3; the direct proportionality to the solubility of cocrystal former was not 
observed. Thus dissolution study was carried out with 2. Attempts to study cocrystal 1 
were unsuccessful. The scaling up of the product was attempted which resulted in the 
precipitation of isonicotinic acid with the cocrystal.  
As explained in section 2.3, UV/VIS was used to carry out dissolution 
experiment. As quercetin did not show any absorbance in water, a suitable solvent in 
which the cocrystal is soluble and shows absorption was found.  
(c) 
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The first choice of the solvent was 1:1 ethanol/water (V/V%) since previous 
studies were carried out in the same solvent system. The standard calibration curve was 
plotted by preparing standard solution of a cocrystal in EtOH/water system. The bulk 
powder of a cocrystal was sieved in order to get the particle size between 53-75 m using 
ASTM standard sieves. Experiment was carried out in set of three using 80 ml of the 
solvent and 800 mg of cocrystal. The resulting slurry was stirred for four hours and at 
regular intervals of time an aliquot was drawn, filtered through 0.25 m nylon filter, 
diluted with appropriate amount of same solvent system and UV absorption was 
recorded. The result is plotted as concentration (mg/ml) Verses time (min) (Figure 3.15).  
 
 
Figure 3.15: Dissolution profiles of dihydrate of 1:1 cocrystal of quercetin 
and theobromine, in 1:1 EtOH/Water (V/V%) system at 360 nm 
It can be viewed from the plot that the solubility of the cocrystal maximizes 
within first five minutes and then slowly goes down to that of quercetin dihydrate. But 
the solubility of the quercetin has been improved by approximately 1.5 fold. Even though 
it is not a significant change it can be concluded that solubility of cocrystal is 
independent of the solubility of cocrystal former. 
In conclusion two novel cocrystals of quercetin have been developed using crystal 
engineering strategies. As expected from CSD statistics in case of 1, acid…pyridine 
supramolecular heterosynthon has been observed. Observed quercetin dimer in quercetin 
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dihydrate and cocrystal of quercetin isonicotinamide is also present in both cocrystals (1 
and 2).The tendency of theobromine forming dimer leaving carbonyl moiety as hydrogen 
acceptor is also observed. Anhydrous cocrystals of 1 and 2 are found to be unstable. 
Dissolution study of 2 shows increase in solubility of quercetin dihyrate and similarly as 
discussed in case of PA, direct proportionality between solubility of cocrystal former and 
solubility of cocrystal is not observed.   
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4. CONCLUSION AND FUTURE DIRECTIONS 
Development of crystal engineering has led the foundation for supramolecular 
chemistry. The importance of supramolecular chemistry has been established by a vast 
array of applications. Discovery of new forms of drugs such as hydrates, solvates, 
polymorphs and cocrystals are overcoming the problems associated with drugs such as 
stability, solubility and bioavailability. Cocrystals have proved their importance in this 
regards and attracting pharmaceutical industries vastly. Using the strategies of crystal 
engineering the work herein has led to develop novel cocrystals of protocatechuic acid 
and quercetin with pharamaceutically accepted molecules (cocrystal formers) such as 
caprolactam, isonicotinamide, isonicotinic acid, theophylline, nicotinamide and 
theobromine. Cocrystals are synthesized and structurally characterized. Cocrystals of 
protocatechuic acid establish its use as cocrystal former. 
Furthermore the effect of these cocrystals has been studied in regards with the 
solubility of pure protocatechuic acid and quercetin. Dissolution studies of protocatechuic 
acid have been carried out to study the trends in the solubility of cocrystals with respect 
to a cocrystal former. The predicted direct proportionality has not been observed. But the 
trend in the melting point of a cocrystal and its solubility has been observed. As the 
melting point of a cocrystal increases the solubility decreases. Thus crystal packing of a 
cocrystal influences its solubility. The study herein contributes in the limited literature 
available regarding to the predictability of cocrystal solubility.  Attempts to improve 
solubility of quercetin via cocrystallization were achieved. Quercetin theobromine 
dihydrate cocrystal results in 1.5 fold increase in solubility of quercetin. As observed in 
case of protocatechuic acid, direct relationship between solubility of quercetin and 
theobromine is not observed. Thus evaluation of physicochemical properties of 
pharmaceutical cocrystals and its predictability is an important area for additional 
research. The results reported herein could be the subject of future contributions. 
 
